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PROTOCOL 
 
 
TITLE 
 
A study of different clinical and biochemical parameters in polycystic ovary syndrome (PCOS) 
affecting ovulation induction outcome and fertility potential. 
 
 
LITERATURE REVIEW 
 
The polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of 
reproductive age.  In 1935 Steyn and Leventhal1 described the association of amenorrhoea, obesity,  
infertility,  hirsutism and bilateral enlarged ovaries.  Till today the diagnostic tools in use remain 
topical and controversial.  There are two definite schools of thought regarding the diagnosis of 
PCOS.  In the UK the classical ultrasound features2 are the cornerstone of the diagnosis which 
includes the clinical and biochemical presentation.  On the contrary, in the USA, PCOS is 
diagnosed on the clinical and biochemical evidence with the exclusion of CAH, 
hyperprolactinaemia and hypothyroidism.3 
 
Fortunately in 2003 the Rotterdam consensus statement4 was made to give clinicians guidance in 
the diagnosis of PCOS. This statement concluded that the diagnosis of PCOS could be made if two 
of the following features are present: chronic anovulation; polycystic ovaries on ultrasound; 
hyperandrogenism and exclusion of other endocrinopathies.   
 
Familial clustering of cases suggests that genetic factors play an important role in the diagnosis of 
PCOS.  Using a candidate gene approach, Franks et al5 found evidence for the involvement of two 
key genes in the aetiology of PCOS.  They suggest that the steroid synthesis gene CYP 11a and the 
insulin VNTR regulatory polymorphism are important factors in the genetic case of PCOS.  It is, 
however, unlikely that these two are the only genes involved in the aetiology of PCOS. 
 
On the basis of the theory that hyperinsulinaemia negatively effects ovulation and that it is an 
important role-player in the pathophysiology of PCOS, it is postulated and has been proven that 
insulin sensitisers may improve the endocrine imbalances and result in normal menses, ovulation 
and normalisation of hyperandrogenism.3  It is also known that obesity on its own,  and in 
association with hyperinsulinaemia, is associated with relative gonadotropin resistance.6  By using a 
simple formula we can isolate the hyperinsulinaemia/insulin resistant patient and commence with a 
combination of weight loss and insulin sensitisers.  At this stage the HOMA (homeostasis model 
assessment) has been proven to be of great success in identifying the scenario.7
 
HOMA = fasting insulin x fasting glucose  
22,5  
 
The value of more than 2,5 is generally accepted as insulin resistant, the same is true for a fasting 
insulin level of more than 17 IU/ml. 
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The HOMA is not the only method to use for the diagnosis of insulin resistance(IR). A more 
scientific method is the euglycemic clamp test. This test is unfortunately very expensive and time 
consuming. This is one of the main reasons why the HOMA remains the most frequently used 
diagnostic test for Insulin resistance in PCOS patients in the gynaecological clinic. Very recently an 
article published concluded that the HOMA is not very sensitive to diagnose IR in lean type 2 
diabetic patients.8 Other tests also available as markers of IR is fasting insulin/glucose levels9 and 
hypertrigliseridemia.10 For the reasons mentioned, we will use the HOMA in combination with 
fasting insulin levels to diagnose IR. 
 
Numerous articles have been published regarding the optimal protocol for ovulation induction in the 
PCOS patient.  Obesity is defined as a BMI of greater then 30kg/m2 and is found in 30 – 50% of 
women with PCOS.11  As mentioned, obesity on its own is associated with ovulation resistance.  
Even a minor weight loss of 5% often result in normalisation of cycles and ovulation.12
 
Clomiphene citrate (CC), an anti-oestrogen, is the drug most regularly used for ovulation induction.  
The primary site of action is the hypothalamus where it binds to estrogen receptors and blocks the 
negative feedback effect of circulating estrogens and ultimately results in an increase in 
gonadotrophin releasing hormone secretion.13  As previously mentioned, insulin sensitisers is more 
frequently apply to induce ovulation induction in the PCO patient. 
 
In financially restricted clinics ovarian drilling remain an effective alternative in CC-resistant 
anovulatory women with PCOS.14  On the other hand,  in private non-financial restricted clinics,  the 
debate regarding the optimal ovulation inducting protocol is far from settled. In an article 
published,15 the author concluded that a  low dose of purified FSH is a very effective mode of 
induction,  whether if it is the best,  remains to be confirmed. They also found a minimal incidence 
of hyperstimulation with FSH. We are still awaiting results of good randomised trials of 
recombinant FSH.  In a Cochrane Review, ovarian drilling for OI was critically assessed.  The 
conclusion was that ovarian drilling was not better, but also not less effective than gonadotropin 
therapy as a secondary treatment for CC-resistant women.  In a recent article14 an insulated needle 
was used for the ovarian drilling.  They concluded that ovarian drilling is an effective alternative 
treatment in CC-resistant women and that an insulated needle is associated with a minimal amount 
of adhesion formation. 
 
Very recently aromatase inhibitors proved to be very successful to achieve ovulation induction.16  
Aromatase is a sytochrome P450 hemoprotein-containing complex that catalyses the rate limiting 
steps in the production of estrogens,  that is,  the conversion of androstenedione and testosterone to 
estrone + estradiol.17  The hypothesis of ovulation induction with aromatase inhibitors is based on 
the fact that these drugs may act locally in the ovary to increase follicular sensitivity to FSH.18  
Ovulation induction can also be achieved by releasing the hypothalamus or pituitary from estrogen 
negative feedback on GnRH and gonadotropin secretion,  resulting in an increase gonadotropin 
production which could stimulate ovarian follicular development.18
 
When and if the PCOS individual falls pregnant, the belief is that the LH hypersecretor is associated 
with an increase of miscarriages.  In a recent article this finding was challenged.  The author 
concluded that LH hypersecretion was not associated with an increased miscarriage rate.19  Whether 
LH hypersecretion is associated with poorer OI response remains controversial. 
 
It is well known that PCOS has long-term metabolic effects.  To screen for insulin resistance may 
identify these patients.  In a very recent article published in Diabetes Care, they concluded that a 
combination of fasting insulin and triglyserides is a very simple and accurate method to screen for 
insulin resistance.20 
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AIMS OF THE STUDY 
 
Chapter 1 presents a literature study on the diagnostic debate of PCOS. The literature study 
includes a discussion of the recent Rotterdam consensus statement regarding the diagnosis of 
PCOS. This is followed by a discussion on the essential work-up of the patient presenting with 
PCOS. Finally, chapter 1 presents a discussion on the complexity of the different variations in 
women presenting with PCOS. 
 
Chapter 2 is a literature review on ovulation induction methods in patients who present with 
PCOS. This literature study puts special emphasis on the different available methods used for 
ovulation induction in women with PCOS and the profounding effect weight loss will have in 
managing these patients.  This chapter also addresses the use of newer agents, like aromatase 
inhibitors (Letrozole), and the current role of each of these agents in ovulation induction protocols. 
 
Chapter 3 is a literature overview on the effect of Metformin in Clomiphene-resistant PCOS 
women. The inclusion criteria of this review was all prospective randomized trials where Metformin 
was added for ovulation in the Clomiphene-resistant PCOS patient. The data is presented as a meta-
analysis. 
 
Chapter 4 is a prospective randomise control trial to evaluate the benefit of metformin if added to 
Clomiphene in a primary ovulation induction protocol in comparison to Clomiphene alone. This 
chapter also evaluates all factors influencing ovulation outcome. Finally in the discussion section all 
the recent studies published addressing this topic were reviewed. 
 
Chapter 5 is a literature review to evaluate the classification systems for semen parameters and the 
in vivo fertility potential. This data is also used to establish fertility/subfertility thresholds for semen 
parameters. 
This chapter also presents the results of a prospective and retrospective study of the semen analysis 
of the partners of women with PCOS. We believe that this population presents the best reference 
group to study the semen profile of the general male population. 
 
Chapter 6 is a summary of the results of these studies and serves as an evidence based approach for 
ovulation induction in women with PCOS. 
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MATERIALS AND METHODS 
 
1. Literature review 
A literature review, using MEDLINE, will be performed to assess the biochemical and clinical 
profile of the patient presenting with PCOS. The long-term complications of the syndrome will be 
discussed to highlight the utmost importance of lifestyle changes as the primary step in the 
management of the patient with PCOS.  This review will also include all different options of 
ovulation induction regimens available in patients with PCOS, who desire a pregnancy. 
 
A structured literature review will also be performed to assess the efficacy of metformin in the CC-
resistant patient. In this review we will only use prospective randomised trials available and aim to 
present the data in the form of a meta-analysis. We will also focus on other management options for 
the CC-resistant patient.  
 
 
2. The study 
This is a prospective study at the clinics mentioned. All patients will be diagnosed as having PCOS 
according to the Rotterdam statement. The patients diagnosed with PCOS will be motivated to loose 
at least 5% of their body weight.  Patients will be encouraged to follow a fat free diet and motivated 
to participate in exercises for at least 40 minutes per day for 3 days per week.  Base line bloods will 
consists of FSH, LH, fasting insulin and glucose, lipid profile, TSH, prolactin, 17OH Progesterone, 
DHEAS, SHBG and testosterone (four tubes). A gynaecological ultrasound will also be performed 
at presentation. All patients diagnosed with PCOS will be motivated to loose at least 5% of their 
body weight. The BMI of all these patients will be calculated and monitored at the follow-up visits. 
 
3. Inclusion criteria 
All patients diagnosed with PCOS will be included in the study. If they have not lost weight, they 
will also be included. 
 
4. Exclusion criteria 
A patient presenting with any other reason of anovulation or hirsutism.  
 
The partners of all the patients diagnosed with PCOS will be asked to give a semen sample. All 
semen samples will be investigated according to the Tygerberg Strict Criteria. If the morphology is 
in the P-pattern (poor pattern) group, all slides will be evaluated by one observer, TFK. 
 
The available data will give a profile of the semen analysis of the partners of PCOS-patients. This 
profile of the semen analysis of the partners of the PCOS patient will provide a possible prediction 
of the semen profile of the general male population.  
 
Patients diagnosed with PCOS and motivated to loose 5% of their body weight will be randomised 
on different ovulation management protocols as outlined in the following algorithm. 
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OVULATION INDUCTION PROTOCOLS 
 
Resistant
Clomiphene 100 mg/d
1 cycle, days 3-7
Resistant
Clompihene 50 mg/day,
1 cycle, days 3-7
Metformin 6/52
A
Resistant
Clomiphene 100 mg/day,
1 cycle, days 3-7
Resistant
Clomiphene 50 mg/day
1 cycle, days 3-7
B
 
If leg A is selected, the patient will receive metformin 850 mg b.d. for 6/52.  Ovulation will be 
monitored with ultrasound of follicles and confirmed with day 21 progesterone.  If the patient did 
not ovulate on metformin alone, clomiphene citrate 50mg/day, days 3-7 will be added.  Ovulation 
will be monitored as above.  If still anovulatory, clomiphene citrate will be increased to a maximum 
of 150 mg/d, days 3-7.  If leg B is selected, clomiphene citrate 50mg/day day 3-7 will be used, and 
ovulation monitored as mentioned.  If still anovulatory clomiphene citrate will be increased to a 
maximum of 150 mg/d, days 3-7.  
 
Regression analysis of the available data will be conducted to establish the biochemical and clinical 
profile of the patient resistant to clomiphene and metformin.  By using the regression analysis, we 
will attempt to identify which of these factors influence ovulation outcome. 
 
With the available data of the semen profiles of the partners of these patients, we will also attempt 
to use this database as a possible reflection of the semen analysis of the normal population. 
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STATISTICS 
 
A power calculation was performed to assess the number of patients needed to do the regression 
analysis. The statistician, Dr C Lombaard did a two group test to calculate the numbers to 
randomise. A two group test with a 0.050 one-sided significance level will have a 90% power to 
detect the difference between a Group1 proportion of 0,500 and a Group 2 proportion of 0,800 
(odds ratio of 4,00) when the sample size in each group is 42. 
 
 
SETTING 
 
1. Tygerberg Fertility Clinic. 
2. Reproductive Institute at Vincent Pallotti. 
 
 
ETHICAL APPROVAL 
 
Was obtained: 2003/013.  
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CHAPTER 1 
- 2 - 
DIAGNOSTIC FEATURES OF POLYCYSTIC OVARY SYNDROME 
 
1.1 INTRODUCTION 
Polycystic ovary syndrome (PCOS) is one of the most common endocrinopathies in women.1 It was 
first described by Stein and Leventhal in 19352, by the association of infertility, obesity, hirsutism 
and bilateral enlarged polycystic ovaries. As a syndrome, PCOS has consequently over the years 
followed an interesting history, with much debate and often poor consensus regarding its diagnostic 
criteria. A variety of histological, biochemical and sonographic features have been described, but 
until recently no general agreement on definition has been reached. 
 
1.2 DEFINITION: THE DIAGNOSTIC DEBATE 
The National Institute of Health (NIH) in Bethesda, USA. held its first international consensus 
conference on PCOS in April 1990 – which ironically made obvious that there was no true 
consensus.3 Nonetheless, a clinical and working definition emerged from the United States 
following the NIH conference. This suggested that diagnosis of PCOS consisted of chronic 
anovulation with biochemical evidence of hyperandrogenism and the exclusion of other causes, 
such as hyperprolactinaemia and non-classical congenital adrenal hyperplasia (NCAH).3,4 Ovarian 
morphology on sonar was not regarded as part of the criteria. In other words, diagnosis is made on 
clinical and biochemical criteria alone. 
 
On the other hand, the predominantly European working definition of PCOS5 comprises 
sonographically diagnosed polycystic ovary morphology – usually using the ultrasound criteria 
associated with oligomenorrhoea or amenorrhoea and/or signs of hyperandrogenaemia.6
 
1.3 ROTTERDAM ESHRE/ASRM-SPONSORED PCOS CONSENSUS WORKSHOP 
May 2003 brought the Rotterdam consensus workshop on polycystic ovary syndrome, sponsored by 
European Society for Human Reproduction and Embryology (ESHRE) and the American Society 
for Reproductive Medicine (ASRM). This workshop was attended prominently by well-published 
authors from both sides of the Atlantic. A ‘consensus statement’7 was released on the revised 2003 
diagnostic criteria, and proves to be detailed and inclusive. The report was based on clinical 
evidence rather than majority opinion. 
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In essence, there are three major criteria, with two out of three required for diagnosis: 
 Oligo- or anovulation;  
 Clinical and/or biochemical signs of hyperandrogenism (with the exclusion of congenital 
adrenal hyperplasia, Cushing’s syndrome, androgen-secreting tumours, thyroid abnormalities 
and hyperprolactinemia); 
 Polycystic ovaries on ultrasound.  
 
The report further acknowledged the problems with this criteria with regards to trial protocol and 
data. For example, where pregnancy is the trial outcome, of course the inclusion criteria of 
anovulation is clearly of significance. However, where clinical improvement of hirsutism is the 
outcome, less emphasis need be placed on ovulatory function.  
 
The statement entails a detailed discussion on the terms ‘hyperandrogenism’ – both clinically and 
biochemically, with specific reference made to the limitations of laboratory measurement of 
circulating androgens and comment that such evidence is not required as proof of clinical 
hyperandrogenism.  
 
Whether this carefully researched and constructed document will be used as a general reference in 
its scientific research field, will only become known in hindsight. Interestingly, Adam Balen from 
the United Kingdom, who presented at the consensus workshop the report on the revised definitions 
of ultrasound assessment, co-authored an article on the clinical overview on PCOS8. In this paper, 
he defined PCOS as a sonographic finding of PCOS plus either oligo- or amenorrhoea, obesity or 
hyperandrogenism.  
 
Another prominent figure on the scientific committee of the workshop, Ricardo Azziz of the US, 
also published a prevalence study in June 2004.9  In this study he used the NIH inclusion criteria for 
his definition. Both these examples emphasises the problems with adopting a new definition in a 
scientific field. 
 
1.4 ORIGINS AND POTENTIAL GENETIC DETERMINANTS 
The first signs of PCOS may be an early adrenarche with an early appearance of pubic hair.10 It is 
increasingly being recognised that oligomenorrhea in adolescence may be one of the first 
manifestations of PCOS.11-13 Although PCOS is not diagnosed until two to three years after 
menarche, it is believed its origins lie in childhood or fetal life, since excess androgen exposure to 
animals in utero produces PCOS-like features.14-17 The severity of hyperinsulinaemia manifest in 
  
- 4 - 
adulthood in over 50% of even normal weight women with PCOS is influenced by both genetic and 
environmental factors, particularly obesity.18 Consequently, although a woman may have the 
predisposition to PCOS, whether genetic or environmental, it is the development of insulin 
resistance due to the deposition of adipose tissue that leads to the manifestation of the phenotype of 
PCOS. Hence it is then also possible that with weight loss she may loose some of the features of 
PCOS.19-23
 
There appears to be a genetic basis for PCOS as evidenced by this familial concordance, with 24% 
of mothers and 32% of sisters being affected.24 The syndrome appears to have an autosomal 
dominant mode of inheritance, with premature balding in men as the putative male phenotype.24 
Genetic linkage with insulin resistance and obesity has been reported via the common allelic 
variation at the VNTR locus in the promoter region of the insulin gene. Anovulatory 
hyperinsulinaemic women are more likely to have inherited this class III/III allele, particularly from 
their fathers.24 
 
The ovarian androgen production in women with PCOS is accelerated due to the increased ovarian 
theca cell androgenic enzymatic activity of 3 beta hydroxysteroid dehydrogenase (HSD) 17 alpha 
hydroxilase/C17,20 lyase, a product of CYP 17.25 The commonly found associated metabolic 
derangement of insulin resistance in PCOS is believed to be due to impairment of the ovarian 
insulin signal transduction augmenting4 cytochrome P450scc, the rate-limiting step in ovarian 
steroidgenesis, and cytochrome P450c17A, the androgenic enzyme 17 alpha hydroxylase/C17,20 
lyase.25,26
 
Genetic abnormalities that produce these altered enzyme activities have been difficult to determine. 
Possible mutations linked to these alterations are associated with the CYP21 gene27 and the insulin 
receptor.28 Elevated plasminogen activator inhibitor-1 (PAI-1) has been implicated in the increase 
propensity towards miscarriage and cardiovascular risk factors amongst women with PCOS.29 The 
presence of an increase in PAI-1 results in a higher incidence of thrombosis.  In this study, it has 
been suggested that there is a higher level of PAI-1 among women with PCOS, which among other 
risk factors, will lead to an increase in cardiovascular complications.29
 
It would appear that there are many genetic polymorphisms in women with PCOS and, hence, the 
influence of an adverse environment (whether antenatal, due to excess androgen exposure during 
childhood, or in adulthood due to obesity), on the genetic predisposition leads to the appearance of 
the PCOS phenotype.30  
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1.5 PREVALENCE 
The assessment of the prevalence of PCOS is fraught with problems. Data are often difficult to 
compare from one study to another due to the inconsistency in standardisation of diagnostic criteria, 
making meta analyses difficult to perform. The inadequacies of the NIH and European systems of 
classification has become obvious, both in the interpretation of data and also in the diagnosis of 
PCOS. 
 
We know that the finding of polycystic ovaries (PCO) alone does not necessarily indicate the 
presence of the syndrome.31 Prevalence studies for these sonographic ovarian findings place the 
incidence in the order of 17-22%, figures that seem remarkably constant worldwide.32-35  Only 7% 
of the eumenorrhoeic women in Polson’s 1988 study of 257 women had polycystic ovaries.32 In 
contrast, 86% of women with irregular cycles had PCO. Transvaginal ultrasound places this figure 
somewhat higher, at 21-28%, and it appears that younger women have a higher incidence of PCO 
than women over 35 years.34 Many of the subjects recruited in the Polson study did in fact have 
clinical problems, although they had not sought medical attention for them, demonstrating the 
difficulty with performing such studies in a “normal” population group.32
 
A 3-11% prevalence of the syndrome is reported, depending on the criteria used for definition.34 A 
recently published USA prevalence study9, on 347 women seeking a pre-employment medical, 
found the prevalence of PCOS at 6,6% using modified NIH criteria of oligo-ovulation rather than 
amenorrhoea. It also emerged that 86% of women presenting with both menstrual dysfunction and 
hirsutism had PCOS, whereas only 8% with menstrual dysfunction alone (no hirsutism) had PCOS. 
In this study, prevalence rates between black and white subjects were not significantly different. 
 
A problem with the NIH definition arises in cases where clinically the patient must have the 
syndrome although she does not comply with the criteria. For example, a woman with polycystic 
ovaries and hyperandrogenism who is ovulatory would, by NIH criteria, not be diagnosed as PCOS. 
However, an anovulatory woman with hyperandrogenism but sonographically normal ovaries will 
benefit from the diagnosis by the European criteria. 
 
1.6 CLINICAL PRESENTATION 
As the most common of endocrinopathies and reproductive disorders in women, it is essential that 
we be aware of PCOS and detect the obvious signs to enable timely diagnosis. It is presented 
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clinically primarily by menstrual irregularity, androgen excess (hirsutism), acne, androgen-
dependent alopecia and infertility.4
 
The first of these clinical features, menstrual irregularity, is subsequent to ovulatory dysfunction. 
This may be defined by a history of eight or fewer menstrual cycles in a year, or menstrual cycles 
that are shorter than 26 days or longer than 35. Alternately, it is indicated where cycle length is 26-
35 days and a day 22-24 (mid-luteal) progesterone of less than 4ng/ml confirms anovulation.9
 
Over the last decade we have become more aware of the higher prevalence of metabolic problems 
associated with PCOS, the so-called metabolic syndrome.36 Women with this syndrome are 
frequently obese, with increased risk of hyperinsulinemia, impaired glucose tolerance (IGT) and 
even frank diabetes. An association with hypertension and dyslipidemia is also well described in the 
literature.7 The consequent cardiovascular risk implications make clinical detection of polycystic 
ovary syndrome and further identification of its metabolic sequelae a very relevant health issue. In 
fact, the ESHRE/ASRM 2003 statement includes a consensus guideline regarding indications for 
screening for metabolic disorders in PCOS (Table 1).7 Chronic anovulation also implies unopposed 
oestrogen and a consequent increased risk of endometrial carcinoma.  
 
Azziz discusses an approach to screening hirsute woman in clinical practice from a cost-effective 
perspective.37 In his guideline, he suggests that all hirsute women first be screened for ovulation, 
even those claiming to be eumenorrhoeic, because in fact 40% of these are oligo-ovulatory. He 
further recommends that oligo-ovulatory hirsute women be screened via TSH (thyroid stimulating 
hormone) (for coincidental thyroid dysfunction) and via 17-hydroxyprogesterone (to exclude 
NCAH). He recommends that routine gonadotrophin testing not be done, since only 50-60% of 
PCOS subjects have an elevated LH/FSH ratio. This may at best confirm what is suspected, but is 
often erroneously used to exclude the diagnosis. Screening must be done for diabetes, as 30% of 
PCOS subjects have IGT and 8% frank type II diabetes. Routine sonogram of the hirsute patient is 
not considered necessary, although it stands to reason that where there are other suggestive 
symptoms of PCOS, ultrasound should form part of the diagnostic analysis.38
 
Obesity is an important association with PCOS. We know that response to treatment is reduced with 
increased BMI. Weight loss itself may be associated with attenuation of symptoms and reduction of 
circulating androgens and insulin, and even spontaneous ovulation. Weight loss has no effect on 
gonadotrophin secretion though.31
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Obese patients may reveal the presence of a cutaneous indicator of hyperinsulinaemia called 
acanthosis nigricans, an association described in 1980 by Barbieri and Ryan as the “HAIR-AN” 
syndrome (hyperandrogenism, insulin resistance and acanthosis nigricans).4
 
An interesting study assessing the effectiveness of interviewing as a means of predicting PCOS as a 
less cost-limiting and time-saving approach was also done.24 Instead of costly biochemical testing, 
the questionnaire centred on androgenic symptoms and was given to patients, their mothers and 
sisters. The questionnaire consisted of the history of possible androgenic symptoms of PCOS and 
was presented to patients and their first degree female relatives, who were also evaluated by 
physical and laboratory investigations. The sensitivity, specificity and positive predictive value 
(PPV) and negative predictive value (NPV) for the detection of PCOS by interview, were 
calculated.  The NPV of the proband interview was significantly lower for sister than for mothers 
(82% vs 100%, respectively; p-value < 0.5).  When the family member completed the written 
questionnaire directly, the specificity and NPV of self-reporting were equally high (> 90%), for 
both mothers and sisters. Thus direct interviewing of PCOS patients, or their mothers and sisters, 
reliably predicts reliable status, but patient interview alone, will not predict PCOS in almost 50% of 
the affected sisters.  
 
1.7 DIAGNOSIS 
1.7.1 Ultrasonography/imaging 
The most widely accepted sonographic criteria of PCO for almost 20 years was described in 1985.6  
The PCO was defined as the presence, in one plane, of multiple cysts, 2-18 mm in diameter, 
distributed evenly around the ovarian periphery, with an increased ovarian stroma. The Adams 
criteria6 have been adopted by many subsequent studies following this seminal paper on polycystic 
ovaries. 
 
Adams had only transabdominal sonar at her disposal in 19856. The advent of transvaginal 
ultrasound with its greater resolution has today largely superseded the transabdominal approach, 
although the latter still has a very definite place.38 The transvaginal approach, with modern high 
frequency (>6 MHz). probes provide a more accurate view, and especially in obese patients avoids 
the homogenous appearance of ovaries that may be erroneously found on a transabdominal scan. 
 
A paper38, first presented at the ESHRE/ASRM workshop in 2003, provides a comprehensive view 
on the current approach to polycystic ovary imaging. It provides a critical discussion on the 
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methods available today, and enumerates the criteria for definition in women on oral contraceptives 
and in the menopause.  
 
The revised sonographic criteria38 define PCO in the finding of either of the following:  
 12 or more follicles measuring 2-9 mm diameter 
 Increased ovarian volume (>10 cm3) 
 
The presence of a single PCO is sufficient for diagnosis. Distribution of follicles and quantification 
of ovarian stroma is no longer essential to diagnosis. 
 
The recent and innovative techniques of 3-D ultrasound and magnetic resonance imaging (MRI) 
may provide even more sensitive means of detection of the PCO. The 3-D sonar is limited by the 
greater cost, training and data analysis it requires. However, excellent correlation between 2-D and 
3-D measurements for ovarian volume and morphology were reported at the ESHRE/ASRM 
workshop.38  
 
MRI as a diagnostic tool provides superb ovarian imaging, and as such would likely increase the 
detection rates of abnormal ovarian morphology dramatically, but has cost and practicality 
limitations. However, it has a place in other related areas of study.39 Transvaginal colour Doppler 
has demonstrated that polycystic ovaries have an increased ovarian blood flow and blood vessels of 
greater diameter than normal ovaries, in keeping with the well-described feature of ovarian 
enlargement.39 A study using dynamic contrast-enhanced (DCE) MRI has also shown the 
enhancement behaviour of the ovaries of PCOS women corresponding with these findings40, which 
may broaden diagnostic and treatment parameters. DCE-MR imaging as a method has thus far been 
used primarily in the field of breast cancer research, focusing on the assessment of angiogenesis. 
Increased concentrations of biochemical factors associated with this process, such as vascular 
endothelial growth factor (VEGF), have been reported as expressed in human ovaries40. Coupled 
with the finding of increased follicular fluid VEGF levels found in ovarian hyperstimulation 
syndrome patients (OHSS, the most serious iatrogenic complication of ovulation induction), DCE-
MR imaging may in the future be utilised in predicting OHSS. 
 
1.7.2 Biochemical diagnosis 
The pathogenesis and pathophysiology of PCOS is still incompletely understood. What we do 
recognise as inter-related characteristics are insulin resistance (IR), hyperandrogenism and altered 
gonadotrophin dynamics.4 This association between PCOS and disordered carbohydrate metabolism 
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was historically first noted by Achart and Thiers in 1921, as the “diabetes of bearded women”. By 
1980, this PCOS association were demonstrated with hyperinsulinaemia.3,41
 
Insulin resistance may be defined as a subnormal biological response to a given level of insulin. 
Dunaif published a now classic study in 1989 on the association of insulin resistance in PCOS, 
which indicates that the extent of IR cannot be explained by obesity alone.3 IR in obese PCOS was 
greater than in obese normal subjects. Among non-obese women, those with PCOS had higher IR 
than the controls (Fig.1).4
 
Dunaif subsequently sought to demonstrate a causality of relationship between insulin resistance 
and hyperandrogenaemia.3 Ovarian tissue sensitivity to hyperinsulinaemia appears to drive ovarian 
and adrenal androgen production, stimulating proliferation of the pilosebaceous unit and 
suppression of sex hormone binding globulin (SBHG), thereby further increasing the bioavailability 
of free testosterone. The directionality of this relationship is now accepted as probable42, though not 
certain.8
 
We are aware that early detection and treatment of IR and its metabolic sequelae is likely to have 
far-reaching health benefits, but testing does not necessarily identify women who will respond to 
insulin sensitisers, nor does treatment usually normalise their endocrine picture.42 The assessment, 
moreover, of insulin resistance and a clear diagnostic strategy to define its parameters is at present 
still an area of debate.  
 
The gold standard for testing IR is the euglycaemic insulinaemic clamp test, in which insulin is 
administered intravenously at a fixed dose while glucose is simultaneously infused at the rate 
required to maintain the glucose at a predetermined level. It is a method that is expensive, time-
consuming and labour-intensive8. Therefore, it is inappropriate for an office setting. 
 
Homeostatic measurements of fasting glucose/insulin ratios, such as the homeostatic model 
assessment (HOMA), and the quantitative insulin sensitivity check (QUICKI), are the most 
frequently used techniques8. These tests are simple and easy to apply. The HOMA index is probably 
the most commonly utilised formula in our clinical setting, simply calculated by the product of 
fasting insulin (Io) and fasting glucose (Go), divided by constant 22.5. A level above 2,5 generally 
being accepted as consistent with IR. 
HOMA = [Io (uIU/ml) X Go (mmol/L)] / 22.5 
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Both these tests are widely considered to have a good correlation with the clamp technique, and 
may be used in normo- and hyperglycaemic patients.8 A recent study in Greece43 specifically on 
PCOS women failed to demonstrate this correlation. They concluded that metabolic or hormonal 
factors particular to PCOS might have influenced this lack of correlation between their findings and 
those of other insulin resistant groups. Putative markers of insulin resistance42 that are current areas 
of research are homocysteine,44 plasminogen activator inhibitor-1, adiponectin, endothelin-1, SHBG 
and insulin-like growth factor binding protein-1 (IGF-1).44,11 The value of obtaining relatively non-
invasive, sensitive and specific serological markers for insulin resistance holds much appeal. This 
area of research is consequently one of much current interest.   
 
1.7.3 Endocrine diagnosis 
The endocrine hallmarks of polycystic ovary syndrome are hyperandrogenaemia and, to a lesser 
extent, elevated secretion of the gonadotrophin, luteinising hormone (LH).35 Both obese and lean 
women have an increased, 24-hour, mean concentration of LH, with an increased pulse frequency 
and amplitude.4,45 This may suggest the presence of a hypothalamic defect in PCOS3, but it is more 
widely accepted that these abnormalities of gonadotrophin release are in fact secondary to ovarian 
pathology and chronic anovulation, with the polycystic ovary itself central to the pathogenesis of 
the syndrome.31  
 
Androgen production by the ovarian theca cells is LH-dependent. It would thus appear that the 
excess androgen production is subsequent to elevated LH levels, supported by the finding that 
suppression of LH by gonadotrophin releasing hormone analogues or the oral contraceptive 
suppresses androgen levels.4
 
Follicle stimulating hormone (FSH) concentrations are usually in the midfollicular range of 
eumenorrhoeic women, but lower than those in the early follicular phase.4,35 Whether this relative 
insufficiency plays a more direct causative role in anovulation is contentious as it has been 
postulated that threshold levels for the initiation of ovulation may be inadequate. The finding that 
most women with PCOS respond to clomiphene citrate, which itself works by stimulating pituitary 
release of FSH, provides supporting evidence for this hypothesis.4
 
A characteristic finding is the increase of LH relative to FSH. Some 50-60% of subjects have an 
elevated LH/FSH ratio, with a ratio37 greater than 2:1 being commonly accepted as consistent with 
PCOS35. Because of the pulsatile nature of gonadotrophin release, however, a single blood assay 
may fail to detect this.3 Assessment of serum concentrations of gonadotrophins, and LH in 
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particular, is limited by data that reflect divergent results with different assay kits on the same 
serum sample. Assay-related reference ranges may largely attenuate this problem44, which appears 
to be improving from what was experienced a decade ago. 
 
Serum levels of testosterone (T), in particular the free T index, are increased in PCOS averaging at 
50-150% higher than normal.35 The clinical expression of this hyperandrogenism shows a wide 
spectrum, with well-documented racial differences in expression.46 Recently, a study conducted in 
America, was published and the aim of this study was to determine the prevalence of diagnosed 
PCOS. This study took place in Northern California with a very heterogenous set of patients.  The 
files of 11035 women were studied. The authors observed a definite difference in clinical 
presentation and associated risk factors among different racial groups.46 Anovulatory but non-
hirsute women with PCOS have similar levels to hirsute women.35 Testosterone is bound to SBHG, 
the expression of which appears to be linked to BMI via the insulin mechanism. In women with 
PCOS, low SHBG levels have been found to correlate with insulin resistance42, thereby increasing 
the unbound testosterone fraction with its ensuing effects.   
 
Androstenedione (A4) has also been reported as elevated in the PCOS,4,31 but the ESHRE/ASRM 
guidelines exclude it from routine testing in the assessment of hyperandrogenaemia. A small 
percentage of PCOS patients may exhibit elevated levels of dehydroepiandrosterone sulphate 
(DHEAS), though again here evidence for routine testing was lacking, according to the consensus 
statement. Nevertheless, DHEAS and A4 have thus far been accepted widely as additional 
androgens that, like testosterone, may typically be elevated in PCOS, as reported by many 
investigators.9
 
Oestrogen levels in PCOS follow an acyclical pattern as a consequence of anovulatory cycles.31 
Early and midfollicular levels are normal, but there is no preovulatory or mid-luteal increase in 
oestrogen levels.35 With progesterone deficiency and increased peripheral conversion of androgens 
to oestrogen by adipose tissue, unopposed oestrogen results in menstrual dysfunction and irregular 
bleeding, with a long-term increased risk of endometrial carcinoma.4 
 
1.8 PCOS IN ADOLESCENCE 
Another early manifestation of PCOS is often the presence of menstrual irregularity in adolescence. 
Most adolescents with menstrual irregularity47 or persistent acne48 will have PCOS, particularly if 
associated with a raised body mass index (BMI). Menstrual irregularity that does not resolve within 
the first two years of menarche will be associated with the clinical and metabolic features of PCOS 
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in up to 70% of girls.48,49 There is also evidence that the occurrence of precocious puberty is often 
followed by the development of PCOS in adolescence.47,50,51  
 
The therapeutic management of the features of PCOS in this sensitive group of young women, 
beyond simple measures to control excessive weight gain, is essentially limited to control of the 
menstrual cycle using the combined oral contraceptive pill in conjunction with an anti-androgen. A 
more controversial approach has been to treat the underlying hyperinsulinaemia on a long-term 
basis with an insulin sensitiser with or without additional anti-androgenic treatment.30 The third-
generation oral contraceptive pill, either alone or in a combination pill with cyproterone acetate, has 
demonstrable and equal benefit to girls with PCOS with regard to cycle regulation, improvement in 
the Ferriman–Gallway (FG) score, serum androgen profile and lipid profile.52,53
 
In women with PCOS, the addition of metformin to a traditional third-generation combined oral 
contraceptive pill, either with or without cyproterone acetate, leads to an improvement in insulin 
sensitivity, androgen profile, sex hormone-binding globulin and waist–hip ratio in obese subjects, 
with no significant effects on lipid metabolism, although more favourable changes were noted in the 
serum-free androgen levels.53-56
 
The introduction of an oral contraceptive containing drosperinone with anti-mineralocorticoid and 
anti-androgenic properties, the so-called fourth-generation combined oral contraceptive pill, has 
increased the therapeutic options for these young women. Since drosperinone is an analogue of 
spironolactone it antagonises the oestrogen-induced activation of the renin-aldosterone system to 
reduce sodium and water retention. In addition to the beneficial effects with regard to a reduction in 
weight and improvement in androgenic symptoms it also has a more favourable effect on the lipid 
profile than traditional third-generation combined contraceptives.57
 
Many studies58-63 have provided evidence for the hypothesis that size at birth is related to the risk of 
developing disease in later life.  In particular, links are well established between reduced 
birthweight and increased risk of coronary heart disease, diabetes, hypertension and stroke in 
adulthood.  These relationships are modified by patterns of postnatal growth.  The most widely 
accepted mechanisms thought to underlie these relationships are those of fetal programming by 
nutritional stimuli or excess fetal glucocorticoid exposure.  It is suggested that the fetus makes 
physiological adaptations in response to chages in its environment to prepare itself for postnatal life.  
These changes may include epigenetic modification of gene expression.  Less clear at this time are 
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the relevance of fetal programming phenomena to twins and preterm babies, and whether any of 
these effects can be reversed after birth.64
 
1.9 PCOS AND LATER LIFE 
The diagnosis of PCOS has serious implications not only for a woman's reproductive potential but 
also for her future long-term health. 
In a population of women with PCOS, approximately 30% will have impaired glucose tolerance 
(IGT) and up to 10% will have diabetes65,66, while in women with a BMI < 27 kg/m2 the prevalence 
of IGT and diabetes is 10.3% and 1.3%, respectively.65
 
It is a recommendation of the Rotterdam ESHRE/ASRM consensus meeting that women with 
PCOS and a BMI in excess of 27 kg/m2, should undergo a glucose tolerance test and a metabolic 
screen.7
 
Women with PCOS are at an increased risk of an adverse cardiovascular profile. In women with 
PCOS, elevated androgen and insulin levels (Figure 1) are associated with an unfavourable lipid 
profile with an increase in LDL, a decrease in HDL and increases in total cholesterol and 
triglyceride levels.67,68 Women with PCOS are at a 2.5-fold increased risk of coronary 
atherosclerosis67, carotid artery atherosclerosis69 and arterial stiffness compared to controls.70
 
In women with PCOS, unopposed oestrogen arising from chronic anovulation may constitute a risk 
factor for endometrial hyperplasia and cancer, although epidemiological evidence of links between 
PCOS and endometrial cancer is limited.71
 
Despite some reports that the incidence of benign breast disease is increased in women with 
PCOS65, this has not been confirmed and the evidence for an increased risk of breast cancer in 
women with PCOS is lacking.72
 
1.10 CONCLUDING REMARKS 
It is unclear whether PCOS represents a single disorder or a conglomeration of different disorders 
with similar clinical presentation.A clinical presentation or Phenotype of PCOS may also reflect 
different etiology or pathophysiological differences. According to the 1990 NICHD definition, 
PCOS may present as three phenotypes.74
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In a recent article75, it was hypothesised that the three clinical phenotypes of PCOS represent 
different forms of the same metabolic disorder. Three hundred and sixteen women diagnosed as 
having PCOS were evaluated. 
 
The oligo (oligo-ovulation) + HA (hyperandrogenism) + hirsutism phenotype represented 48% of 
subjects, oligo + HA represented 29% of the subjects and oligo + hirsutism represented 23% of 
subjects. These three phenotypes did not differ in mean BMI, waist-to-hip ratio, racial composites, 
degree of oligo-ovulation, prevalence of acne or family history of hyperandrogenic 
symptomatology. However, subjects demonstrating the oligo + HA + hirsutism phenotype were the 
youngest and had the greatest degrees of hyperandrogenemia, hyperinsulinemia and ß -cell 
dysfunction. Patients with the oligo + hirsutism phenotype were the oldest and had the mildest 
degrees of hyperandrogenemia, hyperinsulinemia and ß-cell dysfunction. Subjects with the oligo + 
HA phenotype demonstrated intermediate degrees of hyperandrogenemia and metabolic 
dysfunction.75 This set of data suggested that it is the degree to which the ß-cell is able to 
compensate for the degree of insulin resistance, and not the degree of insulin resistance per se, that 
determines the severity of the phenotype. 
 
They also concluded that the lower levels of hyperinsulinemia are related to lower androgen levels 
and slightly less severe hirsutism, whereas the greater degrees of hyperinsulinemia favour the 
development of hirsutism and frank hyperandrogenism.75
 
Finally, it remains unclear whether the three clinical phenotypes of PCOS described represent a 
continuum within a single population or are the result of differences in underlying pathophysiologic 
mechanisms, and whether the clinical phenotype predicts differences in the long-term risks of these 
patients for developing type 2 diabetes mellitus or cardiovascular disease. 
 
The above study clearly confirms the controversy regarding the possible aetiology and diagnostic 
criteria for PCOS.75
  
The diagnosis and the debate of what encompasses this syndrome are hopefully becoming clearer. 
With the revised 2003 guidelines7, more accurate prevalence statistics ought to become available, 
thereby increasing awareness of a common problem that deserves a high index of suspicion in any 
clinical practice including women of reproductive age. 
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The health impact of PCOS is enormous, and with the increasing prevalence of obesity and diabetes 
worldwide, is likely to increase. 
 
It is therefore of utmost importance to adhere to current diagnostic guidelines. This will help us to 
gain valuable information and conduct non-biased research seeking the answers for this poorly 
understood disease.  
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TABLE 1.  Criteria for the metabolic syndrome in women with PCOS (three of five qualify 
for the syndrome)7 
 
 
Risk factor Cut off 
 
1. Abdominal obesity (waist circumference) >88cm 
2. Triglycerides ≥150mg/dL / ≥1.8mmol/L 
3. HDL cholesterol <50mg/dL / <1.3mmol/L 
4. Blood pressure ≥130/≥85mmHg 
5. Fasting and 2-h glucose from oral GTT Fasting glucose 110-126mg/dL or 6-7mmol/L 
  2-h glucose 140-199mg/dL or 7.8-11.1mmol/L 
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FIGURE 1(a) Potential mechanisms by which defects in insulin metabolism promote increased 
androgen activity at the level of the ovary. (b) Central role of insulin resistance in both the clinical 
presenting features and the long-term sequelae of polycystic ovary syndrome. (Reproduced with 
permission from Moran & Norman Understanding and managing disturbances in insulin 
metabolism and body weight in women with polycystic ovary syndrome.30
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CHAPTER 2 
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OVULATION INDUCTION IN WOMEN WITH PCOS 
 
2.1 INTRODUCTION 
Women with PCOS have an increased incidence of World Health Organisation (WHO) group II 
anovulatory infertility.1  
 
The aetiology of the association of anovulation with PCOS is believed to be hyperinsulinaemia and 
is accentuated by obesity.2,3 Approximately 50% of women with PCOS are overweight4 and indeed 
there is evidence that even normal weight women with PCOS have increased intra-abdominal fat.5 
More than 50% of lean women with PCOS are insulin resistant. 
 
Hyperinsulinaemia and elevated leptin production from adipose tissue lead to increased ovarian 
androgen production by increasing ovarian theca cell cytochrome P450-scc and “cytochrome 
P450c-17” enzyme activity6, as well as by increasing the frequency of luteinising hormone (LH) 
pulses, thus augmenting ovarian androgen production.7 This is in addition to the increase in serum 
free androgen levels, due to the inhibition of hepatic sex hormone binding globulin. The result is 
that serum and ovarian androgen levels are raised in association with impaired folliculogenesis. 
Methods employed to induce ovulation consist of weight loss, anti-estrogens, insulin sensitisers, 
gonadotrophins, laparoscopic ovarian drilling and letrozole.1
 
2.2 WEIGHT LOSS 
As described, obesity is very common in women with PCOS.  It is also very important to 
distinguish between different localisations of fat deposits. Despite not distinguishing between lean 
and fat mass, BMI (body mass index, weight in kg per height in m2) is a useful clinical tool that 
correlates reasonably well with adiposity. It is also apparent that body fat distribution has a crucial 
impact on metabolic and reproductive fitness.8,9 Different abdominal fat regions may additionally 
confer differing risks with evidence suggesting abdominal visceral fat correlates more strongly with 
insulin resistance and markers of the metabolic syndrome than subcutaneous fat.10 Waist hip ratios 
(WHR) or waist circumferences provide reasonable estimate of abdominal fat without 
distinguishing between abdominal and visceral fat. Generally, a WHR > 0,9 for men and > 0.8 for 
women defines an increased risk of CVD.11
 
2.2.1 Obesity and reproductive processes 
Reproductive processes are influenced by body weight, and reproductive dysfunction is present 
with both positive and negative extremes of body weight .12 Menstrual disturbances including 
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oligomenorrhoea, amonorrhoea, and anovulation have been consistently related to obesity in 
women.13 This relationship was also observed for infertility. In a subset of the Nurses’ Health 
Study, women with ovulatory disorders were compared to controls with no history of infertility. 
Increased BMI at age 18 was significantly associated with ovulatory infertility.14 Furthermore once 
conception is achieved, an increased risk of pregnancy complications (including gestational 
diabetes) and miscarriage may result with increased weight.15 There is thus a clear association 
between obesity, both in adulthood and childhood, on menstrual abnormalities and consequent 
infertility. 
 
2.2.2 Weight loss and subsequent reproductive improvement 
Resumption of ovulation occurred with weight losses of 5,6 to 6,5 kg in anovulatory women.16 This 
amount of weight loss is generally sufficient to reduce abdominal fat and improve insulin 
sensitivity. A reduction in body weight of 2 to 5% was associated with restoration of ovulation, an 
11% reduction in abdominal fat, a 4cm reduction in waist circumference and a 71% increase in 
insulin sensitivity.17 Large changes in weight may not be needed to restore reproductive function, 
and realistic and achievable target weight loss goals can be set for women to improve their 
reproductive fitness. 
 
2.2.3 How is this weight loss best achieved? 
The NIH document “Clinical guidelines on the identification, evaluation, and treatment of 
overweight and obesity in adults” recommends a multifaceted approach to treating obesity.18 (Table 
1) 
 
2.2.4 Dietetic treatment and lifestyle changes 
Dietary management aims for gradual weight loss (0,5 to 1 kg per week) through energy intake 
reduction and increasing physical activity.19 A low fat (30% of energy and saturated fat 10% of 
energy), moderate protein (15%) and high carbohydrate intake (55%) and increased consumption of 
fibre, wholegrain breads and cereals and fruit and vegetables in conjunction with moderate regular 
exercise (30 to 60 minutes per day) is proposed to aid in weight loss and maintenance both in 
general population and in obese infertile women PCOS.19
 
Smoking is a major risk factor for female sub-fertility, expressed time to pregnancy, for pre-term 
birth and for low birth weight in babies.20 High levels of alcohol intake have been associated with 
reduced fertility and increased risk of spontaneous abortion.21 Cognitive behaviour therapy and 
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reduction of psychosocial stressors can aid in both weight loss and maintenance of the reduced 
weight.22
 
Weight loss should therefore be the first choice of action in obese, infertile women. This goal may 
be difficult to achieve and maintain and it is therefore crucial to identify means to increase the ease 
of achieving and maintaining weight loss. 
Principles identified in the general population and in obese infertile women include adoption of 
healthy eating habits and moderate amounts of low-intensity exercise that can be sustained as 
lifestyle changes.19 (Table2) 
 
2.3 CLOMIPHENE CITRATE 
Ovulatory dysfunction is one of the most common causes of reproductive failure in sub-fertile and 
infertile couples.23 Women with PCOS have an increased incidence of World Health Health 
Organisation (WHO) group II anovulatory infertility.1 Clomiphene citrate (C/C) is the most 
common initial treatment used in anovulatory infertile women. The first clinical trial of C/C therapy 
demonstrated successful ovulation in 80% of women, half of whom achieved pregnancy during 
treatment.24
 
2.3.1 Pharmacology 
C/C is a nonsteroidal triphenylethylene derivate that exhibits both estrogen agonist and antagonist 
properties.25 In general C/C acts solely as competitive estrogen antagonist. About 85% of an 
administered dose is eliminated after approximately 6 days, although traces may remain in the 
circulation for much longer.26 C/C is a mixture of two distinct steroisomers, enclomiphene and 
zuclomiphene. Available data indicate that enclomiphene is responsible for the ovulation inducing 
action of C/C.25,27 The levels of enclomiphene rise rapidly after administration and is cleared from 
the circulation soon thereafter. Zuclomiphene is cleared more slowly and the levels of this less 
active isomer remain detectable in the circulation for more than a month after treatment and may 
accumulate over consecutive cycles of treatment.28
 
The structural similarity to estrogen allows C/C to bind to estrogen receptors (ER). In contrast to 
estrogen C/C binds ER for an extended period of time and eventually depletes ER concentrations.25 
Depletion of the hypothalamic ER prevents correct interpretation of circulating estrogen levels. 
Reduced levels of estrogen block the negative feedback effect of estrogen on the anterior pituitary, 
stimulating an increased secretion of gonadotrophins thus augmenting follicular selection and 
stimulation. 
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2.3.2 Indications  
2.3.2.1 Anovulation 
The causes of anovulation are many and varied. Correct diagnosis may suggest specific treatment 
and many associated conditions may have longer-term health consequences. Thyroid disease, 
pituitary tumors, eating disorders, extreme of weight loss and exercise, hyperprolactinemia, PCOS 
and obesity may be identified. C/C is the initial treatment of choice. However, given its 
hypothalamic site of action, C/C is often ineffective in hypogonadotrophic hypogonadism. 
Associated endocrinopathies should always first be treated appropriately.23
 
2.3.2.2 Luteal phase deficiency 
The corpus luteum is derived from the follicle that ovulates, therefore its functional capacity is in 
part dependant on the quality of the preovulatory follicle development. In this context C/C is one 
logical treatment option for luteal phase deficiency.29 Progesterone levels are typically higher after 
C/C treatment than in spontaneous cycles.30
 
2.3.2.3 Unexplained infertility 
In couples whose infertility remains unexplained after thorough investigation, empiric treatment 
with C/C may be justified. This is particularly true for young couples with a short duration of 
infertility.31 The efficacy of empiric C/C treatment may be attributed to correction of subtle and 
unrecognised ovulatory dysfunction.32
 
2.3.2.4 Standard therapy 
C/C is administered orally, typically starting on the third to the fifth day after the onset of menses. 
The ovulation rates, conception rates and pregnancy outcome are similar regardless whether 
treatment begins on cycle day2, 3, 4 or 5.33
 
Treatment normally begins with a single 50-mg tablet daily for 5 consecutive days, increasing by 
50-mg increments in subsequent cycles until ovulation is induced. Most women ovulate in response 
to treatment with 50 mg (52%) or 100 mg (22%). Higher doses have also been used but less 
successful (150 mg, 12%, 200 mg, 7%).34
 
Lower doses (e.g., 25 mg/day) need to be further investigated in women who demonstrate 
sensitivity to C/C or constantly develop large ovarian cysts.  
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C/C treatment will successfully induce ovulation in approximately 80% of cases. Likelihood of 
response declines with increasing age, body mass index (BMI), and free androgen index.35 
Approximately 70% to 75% of anovulatory women who respond to C/C may be expected conceive 
within six to nine cycles of treatment.36
 
2.3.2.5 Side effects 
C/C is generally very well tolerated. Some side effects are relatively common but they are typically 
modest and manageable. 
 
Vasomotor flushes (hot flashes) occur in approximately 10% of C/C-treated women, typically 
disappear soon after treatment stops.23 Mood swings are also common. Visual disturbances, 
including blurred or double vision, scotomata, and light sensitivity are generally uncommon (<2% 
prevalence) and reversible. There are isolated reports of persisting symptoms and more severe 
complications such as optic neuropathy.37 Whenever visual disturbances are identified it is very 
important to stop treatment and consider alternatives. Less specific side effects include breast 
tenderness, pelvic discomfort, and nausea all observed in 2% to 5% of C/C-treated women.  
 
In addition to the successful ovulation induction action of C/C, C/C also exerts undesirable and 
unavoidable adverse anti-estrogenic effects in the periphery (endocervix, endometrium, ovary, 
ovum and embryo) that may explain the discrepancy between the ovulation and conception rates 
observed in C/C-treated women. However, there is very little or no compelling evidence to support 
these notions. The quality and quantity of cervical mucus production in C/C treatment cycles may 
sometimes be reduced, but rarely to the extent which may interfere with sperm transport or sperm 
survival.38 Limited endometrium proliferation has been observed in some C/C-treated patients,24 but 
the effect is minor or not at all evident in the large majority of women. If endometrium proliferation 
is a problem in a specific patient it would be advisable to use an alternative like letrozole.39-41 
Adverse effects of C/C on mouse ovum fertilization and embryo development have been 
demonstrated in vitro,42 but circulating levels of C/C never reach the concentrations required to 
produce these effects, even after several treatment cycles.28  
 
2.3.2.6 Complications 
2.3.2.6.1 Multiple gestation 
Multifollicular development is relatively common during C/C treatment and the risk of multiple 
gestation is clearly increased to approximately 8% overall.43 The overwhelming majority of 
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multiple pregnancies that result from C/C are twin gestations, triplet and higher order pregnancies 
are rare but may occur. 
 
2.3.2.6.2 Congenital anomalies 
There is no evidence that C/C treatment increases the overall risk of birth defects or of any one 
anomaly in particular.44,45
 
2.3.2.6.3 Spontaneous abortion 
A number of studies have described abortion rates that are not different from those observed in 
spontaneous pregnancies (10% to 15%).46,47
 
2.3.2.6.4 Ovarian hyperstimulation syndrome 
The incidence of ovarian hyperstimulation syndrome (OHSS) in C/C-treated women is difficult to 
determine, as definitions of the syndrome vary widely among studies. Whereas mild OHSS 
(moderate ovarian enlargement) is relatively common, severe OHSS (massive ovarian enlargement, 
progressive weight gain, severe abdominal pain, nausea and vomiting, hypovolemia, ascites and 
oliguria) is rarely observed.23
 
2.3.2.6.5 Ovarian cancer 
Two epidemiologic studies suggested that the risk of ovarian cancer might be significantly 
increased in women exposed to ovulation induction drugs.48,49 In contrast to these results, 
subsequent studies have failed to confirm those findings.50-53 A recent pooled analysis of eight case-
control studies concluded that neither fertility drug use for more than 12 months was associated 
with invasive ovarian cancer.54
 
Taken together, available data suggest that any adverse anti-estrogenic effects of C/C present no 
significant obstacle in the majority of treated women. 
 
2.4 INSULIN SENSITIZERS 
Hyperinsulinemia and insulin resistance play an important role in the pathogenesis of PCOS.55,56 
Hyperinsulinemia enhances ovarian androgen production and decreases serum concentrations of sex 
hormone binding globulin (SHBG), resulting in an increased amount of unbound serum 
androgens.57 Hyperinsulinemia may also increase ovarian E2 production by granulosa cells.58 
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The use of insulin sensitizers may restore the endocrine milieu and promote a normal menstrual 
cycle and ovulation by normalizing serum insulin and androgen levels.59,60,61
 
2.4.1 Metformin 
2.4.1.1 Pharmacology 
Of the insulin sensitising drugs, metformin has been the one studied most widely and has the most 
reassuring safety profile.62 Metformin is a biguanide, it enhances insulin sensitivity in both the liver, 
where it inhibits hepatic glucose production, and the peripheral tissue, where it increases glucose 
uptake and utilization into muscle tissue. By increasing insulin sensitivity, metformin reduces 
insulin resistance, insulin secretion and hyperinsulineamia.63 The most common side effects of 
metformin is nausea, vomiting and other gastro intestinal symptoms.64 Metformin is contraindicated 
in the presence of even mild renal impairment because of a danger of lactic acidosis and it is 
associated with a decrease absorption of vitamin B12.65 There is also no literature about the safety 
of long term use of metformin in young women.  
 
2.4.1.2 Dose 
Most studies or case reports of metformin66-77 but not all,78-80 have demonstrated that metformin 
administered at a dose of 500 mg three times daily (1,5 gr daily) increases menstrual cyclicity, 
improves spontaneous ovulation and promotes fertility. 
 
It is interesting to speculate whether the response rate might have been higher had a dose of 
metformin of 1,000 mg twice daily been administered. In a dose response study of type II diabetic 
patients, the 2,000 mg daily dose of metformin was found to be optimal in improving glucose 
homeostasis,81 and it is reasonable to assume that the higher dose might prove more beneficial in 
women with PCOS as well. 
 
2.4.1.3 Clinical effects 
In a recent systematic review and meta-analysis,65 the authors commented on the proven effects of 
metformin when administered in PCOS patients. 
 
2.4.1.3.1 Ovulation rate 
A statistical significant effect of metformin when compared to placebo was observed (P<0.0001). 
 
2.4.1.3.2 Weight 
No evidence of effect was found from metformin on body weight or body mass index. 
  
- 31 - 
 
2.4.1.3.3 Blood pressure 
The analysis showed a significant reduction for metformin in both systolic blood pressure and 
diastolic blood pressure. 
 
2.4.1.3.4 Insulin 
Metformin had a significant effect in reducing fasting insulin ( P= 0.0001). 
 
2.4.1.3.5 Lipids 
Total cholesterol, high density lipoprotein cholesterol and triglycerides showed no evidence of a 
significant treatment effect with metformin, but low density lipoprotein cholesterol was 
significantly reduced in the metformin group.  
 
2.4.1.4 Metformin and ovulation 
As documented in the meta-analysis,65 metformin showed a significant effect compared to placebo 
on ovulation (P<0,0001). 
 
A recent structured literature review published, reported on the effect of metformin when added to 
clomiphene- resistant PCOS patients. In this review the authors documented a significant effect 
when metformin was added to clomiphene in the clomiphene-resistant PCOS patient.82 (See chapter 
3) 
 
At the time of the meta-analysis65, the question to be answered was, should metformin replace 
clomiphene as primary ovulation induction agent in women with PCOS? Recently 4 prospective 
randomized control trials were published, trying to answer the above question.83-86 (In the 
discussion of chapter 5 the outcome of these trials is discussed). In the study by Legro et al,85 they 
studied 626 patients with PCOS. This is by far the biggest trial and they concluded that C/C was 
superior to Metformin in achieving live birth rates and equal to the combination of Metformin and 
C/C in achieving pregnancies.  
 
2.4.2 Trioglitazone 
Trioglitazone, pioglitazone and rosiglitazone are part of a newer group of insulin sensitizers, the 
thiazolidinediones. 
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Five studies have reported on the use of trioglitazone in PCOS.87-91 Each of these studies 
demonstrated an improvement in  ovulation in the women treated with trioglitazone. The most 
recent trial was a multicenter, one-year study of over 400 women with PCOS.87 This study 
demonstrated a dose-responsive improvement in ovulation with trioglitazone, lending substantial 
weight to the idea that insulin sensitivity influences ovulation. In conjunction with an increase 
insulin sensitivity , trioglitazone therapy consistently reduced circulating free testosterone, 
dehydroepiandrosterone sulfate, estrone, and LH levels and increased levels of sex hormone binding 
globulin.92
 
Because of the reported cases of hepatotoxicity associated with trioglitazone therapy, it has been 
withdrawn from the market in the UK until the issue of hepatotoxicity risk is settled. 
 
Rosiglitazone and pioglitazone related to the same pharmacological group have been reported to be 
safer but clinical experience is still limited.93-95
 
2.5 LAPAROSCOPIC OVARIAN DRILLING 
Laparoscopic ovarian drilling (LOD) has been widely used to induce ovulation in PCOS women 
after failure of treatment with C/C. It was first described in 1984 as a laparoscopic alternative to 
ovarian wedge resection by laparotomy.96  Many authors have reported high ovulation (80%) and 
pregnancy rates (60%) following LOD.96-104 The mechanism of action of LOD is not fully 
understood. It is therefore not exactly clear why some PCOS patients will not respond to LOD. A 
possible explanation is that the amount of ovarian tissue destroyed during LOD is not sufficient to 
produce an effect in some patients.105 It is also believed that ovarian diathermy works by increasing 
the sensitivity of the ovaries to endogenous FSH, and that only a minimal amount of thermal injury 
is required. Another possible explanation of failure to respond may be an inherent resistance of the 
ovary to the effects of drilling.105
 
A retrospective study has determined that three punctures per ovary are sufficient to produce the 
beneficial effect of ovarian drilling.106 A significant side effect of ovarian drilling is the occurrence 
of pelvic adhesions and to minimise this significant risk a fine electrodiathermy needle should be 
employed.107
 
In a recent Cochrane review the authors concluded that there is no evidence of a difference between 
laparoscopic ovarian drilling (with or without medical ovulation induction) compared to ovulation 
induction with gonadotrophins for women with PCOS and C/C-resistance for the outcomes of 
  
- 33 - 
pregnancy and ovulation after 12 months follow up.108 They also stated that multiple pregnancy 
rates are increased with gonadotrophins and are almost nonexistent with ovarian drilling. With 
regard to adhesion formation, there is currently insufficient evidence to favour any one surgical 
technique over another.108
 
In a recent study,105 the authors studied 200 PCOS patients and evaluated the influence of the 
various pre operative characteristics on the ovulation and pregnancy rates after LOD. Women with 
body mass index > 35kg/m2, serum testosterone concentration >4,5nmol/l, free androgen index >15 
and with duration of infertility > 3 years seem to be poor responders to LOD. The authors 
recommended alternative methods of treatment for this group of patients such as weight reduction, 
metformin, gonadotrophin therapy or IVF. In the LOD responders, Serum LH levels > 10IU/l 
appeared to be associated with higher pregnancy rates. 
 
In another study,109 the authors studied 83 women with C/C-resistant PCOS. These women had 
LOD and were followed up post operatively to evaluate factors influencing ovulation outcome. 
They concluded that women who were younger than 13 at menarche, had a LH/FSH ratio below 2 
and a glucose level below 4,5mmol/l were more likely to have persistent anovulation.  
 
LOD may be an alternative choice for C/C-resistant women with PCOS.107,110
 
2.6 CLOMIPHENE AND DEXAMETHASONE 
The use of dexamethasone (0,5 - 2mg from days 2 – 6) as an adjunct to C/C treatment, when 
compared to C/C alone, based on two studies111,112, demonstrated a major benefit with regard to 
ovulation and pregnancy, with the number to treat for each additional pregnancy being only 2,7.113 
The mechanism of action is potentially by suppressing adrenal androgen secretion, facilitation of 
folliculogenesis by augmenting follicle-stimulating hormone (FSH) secretion, or by suppression of 
the large amplitude LH secretion.113 The addition of dexamethasone to C/C may, therefore, may be 
considered in women with a high LH level or with an elevated adrenal androgen, 
dehydroepiandosterone (DHEA) level, although it is recognised that these two studies were not 
entirely comparable and that further research is required.113
 
2.7 GONADOTROPHIN THERAPY 
Gonadotrophin therapy is often used as a second line therapy in anovulatory women with PCOS if 
they were either resistant to ovulation induction with anti-oestrogen treatment or failed to conceive. 
However, women with PCOS are particularly sensitive to gonadotrophin therapy and have a 
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significant chance of multiple follicular development and cycle cancellation.114 In addition, the 
frequent development of multiple follicles leads to the risk of multiple pregnancy and ovarian 
hyperstimulation syndrome (OHSS). To overcome this risk, a “low-dose step-up” protocol is well 
established in fertility practices.115 Treatment with metformin concurrently with low-dose 
gonadotrophin stimulation may improve the mono-follicular ovulation rate.116 In an attempt to 
predict treatment response an article was published assessing initial patient characteristics and the 
subsequent risk of OHSS.117 Initial characteristics predicting multifollicular development were 
hyperandrogenism, increased LH, and increased antral follicle count, and those for better chances of 
ongoing pregnancy in FSH ovulation induction include younger age, lower androgens and lower 
insulin growth factor I.117
 
Gonadotrophin therapy remains a successful option for ovulation induction in C/C-resistant PCOS 
women. 
 
2.8 AROMATASE INHIBITOR TREATMENT 
2.8.1 Introduction 
Clomiphene citrate (C/C) is frequently used for ovulation induction and is highly effective in 
initiating ovulation in patients with PCOS118. However, despite a 75% -80% ovulation rate with C/C 
use, the cumulative pregnancy rate after 6 months of treatment is only 40% - 45%119. 
 
In patients who do not respond to treatment with C/C, metformin can be added (see Chapter 3). 
Gonadotrophins can also be used in the C/C-resistant patient with an increased risk of 
hyperstimulation syndrome and multifetal pregnancies (see discussion on gonadotrophins).  
 
2.8.2 Pharmacology 
Aromatase inhibitors were originally developed for the treatment of breast cancer. Aromatase is a 
cytochrome P-450 hemoprotein that catalyses the rate-limiting step in estrogen synthesis, that is, the 
3-hydroxylation step in the conversion of androstenedione and testosterone to estrone and E2, 
respectively120.  The most widely used aromatase inhibitor is letrozole. It has been suggested that 
letrozole increases endogenous gonadotrophin secretion, as seen with C/C. However, unlike C/C, 
letrozole does not cause a decrease in estrogen receptors121.  
 
2.8.3 Treatment regimens 
In a recent study, 179 patients were prospectively randomised. This study aimed to compare the 
three most common used doses: 2,5, 5 and 7,5mg from day 4 to day 8122. This study reported a 
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significantly higher (P<0.05) number of follicles on the day of administration of human chorionic 
gonadotrophin (hCG) in the 7.5mg group. However, the pregnancy and miscarriage rates were 
similar in the three groups. The authors concluded that it seems that the use of higher doses of 
letrozole offers no advantage in terms of pregnancy rates over the lower (2.5mg) dose.  
 
In another study by Bayar et al123, they compared the use of letrozole with the use of C/C. This was 
a prospective randomised study of 74 patients. In this study the median endometrial thickness on the 
day of hCG administration did not differ between the two groups. The ovulation rates and 
pregnancy rates did also not differ significantly.  
 
2.8.4 Current issues 
In a study by Biljan et al124, the authors evaluated the outcome of 150 babies conceived after the use 
of letrozole and compared this data to a large control group of spontaneous conceptions. The 
outcome of this study suggested that the use of letrozole for infertility treatment might be associated 
with a higher risk of congenital cardiac and bone malformations in the newborns. As a result of this 
study, on November 17th, 2005, Novartis Pharmaceuticals issued a statement to physicians in 
Canada and worldwide advising that letrozole use in premenopausal women, specifically its use for 
ovulation induction, is contraindicated125. 
 
This study was followed by a retrospective study on 911 newborns from women conceived 
following C/C and letrozole treatment126. Overall, congenital malformations and chromosomal 
abnormalities were found in 14 of 514 newborns in the letrozole group (2.4%) and in 19 of 397 
newborns in the C/C group (4.8%). The major malformation rate in the letrozole group was 1.2% 
(6/514) and in the C/C group was 3% (12/397). In addition, the rate of all congenital cardiac 
anomalies was significantly higher (P:0.02) in the C/C group (1.8%) compared to the letrozole 
group(0.2%). 
 
The authors concluded that congenital cardiac anomaly is less frequent in the letrozole group and 
that there was no difference in the overall rates of major and minor congenital malformations 
among newborns from mothers who conceived after letrozole or C/C treatments. 
 
Based on current data letrozole may be an acceptable alternative to C/C as an ovulation induction 
drug in patients with PCOS. 
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TABLE 1.  National Institute of Health Clinical Guidelines for long-term treatment of 
overweight and obesity 
 
Effective weight loss and long-term results – National Institute of Health 
Guidelines 
1. Sensible diet and changes eating habits for long term 
2. Effective physical activity programme sustainable long term 
3. Behaviour modification, reduction of stress, wellbeing 
4. Combination of dietary and behaviour therapy and increased physical activity 
5. Social support by physician, family, spouse, peers 
6. Smoking cessation and reduction in alcohol consumption 
7. Avoidance of “crash diets” and short-term weight loss 
8. Minor roles for drugs involved in weight loss 
9. Avoidance of aggressive surgical approaches for majority 
10. Adaptation of weight-loss programmes to meet individual needs 
11. Long-term observation, monitoring and encouraging of patients who have 
successfully lost weight 
Adapted from 17
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TABLE 2.  Principles for treatment of infertility in obese women 
 
Principles for treatment of infertility in obese women 
Assessment of BMI and waist circumference / WHR 
Assessment of metabolic risk profiles (lipid profile, glucose intolerance), particularly 
in women with PCOS 
Encouraging weight loss through diet/exercise/lifestyle modification 
a) Energy deficit of ∼ 500 – 600 kcal/day 
b) Moderate exercise/ lifestyle modification 
c) Diet composition:  Fat ≤ 30 % of energy (saturated ≤ 10% of energy, reduce 
trans fatty acids, increase mono-unsaturated and polyunsaturated fatty acids).  
Carbohydrate ∼ 55% of energy, protein ∼ 15% of energy 
Reduction of alcohol intake and cessasion of smoking 
Reduction of psychosocial stressors 
Use of a group environment in providing support, aiding weight loss and 
maintainance of weight loss 
Tailoring intervention to a individual’s weight and current dietary and exercise 
patterns (with use of dietitian of appropriate) 
Adapted from 19
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CHAPTER 3 
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IS THE ADDITION OF METFORMIN EFFICACIOUS IN THE CLOMIPHENE-
RESISTANT PCOS PATIENT? (A STRUCTURED LITERATURE REVIEW) 
 
3.1 INTRODUCTION 
Polycystic ovarian syndrome (PCOS) is a very common endocrinopathy among infertile female 
individuals and affects approximately 6% of the general female population1.  The most prominent 
presenting characteristics are anovulation and hyperandrogenism. 
 
The diagnosis of PCOS was recently debated and suggestions followed in the Rotterdam consensus 
statement2. This statement concluded that the diagnosis of PCOS could be made if two of the 
following are present: chronic anovulation, polycystic ovaries on ultrasound, and 
hyperandrogenism2. 
 
Insulin resistance and concomitant hyperinsulinemia are frequently found in obese PCOS women 
(65%)3,4.  The incidence of insulin resistance among lean PCOS women is nearly 20%3.  This 
results in hyperinsulinemia and enhances the LH driven production of androgens from ovarian theca 
cells4. Hyperinsulinemia, insulin resistance and an increase in androgen production are all linked 
together in PCOS patient4,5. It is also known that patients with PCOS and insulin resistance are 
often resistant to ovulation induction. Is the answer in the management of infertile PCOS women 
then the use of insulin sensitizers?  Previous articles have been published where insulin sensitizers 
such as biguanides (metformin)6 and thiazolidinediones (troglitazone), have been used and proven 
to improve metabolic abnormalities in PCOS patients7. Unfortunately, nearly all of these studies 
were observational studies.  (See chapter 2, Discussion Metformin) 
 
Metformin, a biguanide, is normally used in non-insulin dependent diabetes and the mechanism of 
action includes inhibition of gluconeogenesis in the liver and increasing the peripheral uptake of 
glucose. Metformin reduces levels of LH, hyperinsulinemia and also decrease ovarian production of 
androgens8. 
 
Infertility secondary to chronic anovulation is one of the most common clinical presenting features1.  
Clomiphene citrate (C/C) is the standard drug used for ovulation induction in women with 
PCOS9,10,11.  PCOS patients are frequently resistant to C/C and these results in numerous cycles 
where C/C is unsuccessfully used for ovulation induction. The continuous use of C/C has also been 
linked to possible higher ovarian cancer risk12. (See chapter 2, Discussion Clomiphene) The 
possible solution for an optimal protocol in ovulation induction is for the clinician to know the 
  
- 51 - 
optimal time when to introduce insulin sensitizers to improve ovulation induction among PCOS 
patients. 
 
The aim of this literature search is to establish if metformin is efficacious when given to the C/C-
resistant PCOS patient. 
 
3.2 MATERIALS AND METHODS 
This study was reviewed by the Stellenbosch University IRB (2003/013) and approval was given to 
proceed. 
 
Studies were identified using several search strategies. The National Library of Medicine’s 
MEDLINE database was searched form 01 January 1980-2005. The following medical subject 
headings (MESH) were used: metformin, ovulation induction, C/C-resistance. The MEDLINE 
search was performed on titles, abstracts and key words of the listed articles. 
 
Clinical trials comparing two groups of patients were selected only if they met the inclusion criteria 
and if the outcome data were provided to enable statistical pooling of the data. 
 
Our inclusion criteria were prospective randomised control trials where metformin was randomised 
either with placebo or C/C to induce ovulation induction in the C/C-resistant patient. The dosage of 
Metformin used in all articles was 850mg twice a day or 500mg three times a day. Most authors 
defined C/C-resistance as no response in three consecutive cycles to a maximum dosage of C/C 
100-150mg administered day four to eight of the cycle. The primary outcome of interest was 
ovulation.   
 
3.3 VALIDITY ASSESSMENT AND DATA EXTRACTION 
A score was given to each trial using the same scoring system by Soliman et al13. Six 
methodological variables namely, randomization, group demographics, placebo use, follow-up, co-
intervention and patient cycle differentiation were chosen (Table I). Each trial was assessed and 
ranked for its methodological rigor and its potential to introduce bias.  The methodological strength 
of each trial was evaluated in a systematic fashion (Table II). Trials were given scores that were 
divided by the maximum possible score and a percentage performance was given to each trial. 
Performance scores ranged from 50% to 92% for the studies analyzed.   
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3.3.1 Statistical analysis 
The data on the outcomes of each include trial were summarized in two-by-two tables. The odds 
ratio (OR) was calculated for the use of metformin in the C/C-resistant patient. The overall 
combined OR, together with its 95% confidence interval (CI) was calculated using the Mantel-
Haentszel method. This statistic is also presented as the overall effect.  Statistical significance was 
inferred with a two-tailed p value of 0.05 or less. 
 
The weight of each study in each analysis was calculated as inversely proportional to the variance.  
The degree of heterogeneity of studies was calculated using the chi-square test. Where the p-value 
was < 0.05, the OR and 95% CL are still reported, but the applicable studies were re-analyzed to 
find an explanation for any differences. We used a fixed effect analysis because we assumed that 
the intervention was similar in each study.  We also applied a random effect analysis to each data 
set.   
 
3.4 RESULTS 
Twenty trials were evaluated. Eight trials compared the efficacy of metformin in the C/C-resistant 
patient regarding ovulation induction. Six trials met the inclusion criteria and were selected for 
analysis. Three groups were identified regarding the study structure. 
 
There were no significant differences when the fixed effect analysis model was used in comparison 
with the random effect analysis model.  We therefore report only the results obtained with the fixed 
effect analysis. 
 
3.4.1 Group 1 
Four trials were prospective double-blind placebo controlled14,15,16,17. Each of these trials 
randomised metformin with placebo in the C/C-resistant patient. In one trial16 there was no 
difference in outcome. The other three trials14,15,17 had a statistical significant improvement when 
metformin was added to C/C in the C/C-resistant patient (Figure 1). When the data of the four trials 
were pooled the test for the overall effect was p=0.0006 with an OR of 4 and 95%CI of 1.81-8.84. 
 
3.4.2 Group 2 
In two of the trials the randomization was only prospective and not double blind18,19. Each of these 
trials prospectively randomised and compared the addition of metformin with placebo in the C/C-
resistant patient. In both trials there was a statistical improvement when Metformin was added 
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(Figure 2). When the data of the two trials were pooled the overall effect was p<0.00001 with an 
OR of 20.94 and 95% CI of 6.24-70.27. 
 
3.4.3 Combined analysis of groups 1 and 2 
The data of these two groups were combined to increase the numbers and to give the meta-analysis 
more weight (Figure 3). This combined data show an overall effect, p<0.00001 and an OR of 6.82 
with a 95% CI of 3.59-12.96.  
 
3.4.4 Group 3 
The third group consisted of two trials20,21. In these two trials the investigator looked prospectively 
at a cohort of C/C-resistant patients when metformin was added without randomization. 
 
Batukan and Baysal20 added metformin to 29 C/C-resistant patients; 65.2% of these patients became 
pregnant when metformin was added.  In the second study by Parsanezhad et al.21, metformin was 
added to 41 C/C-resistant patients. None of these patients were ovulating before the addition of 
metformin and 13 (39.39%) ovulated after treatment.  
 
3.5 DISCUSSION 
The fertility specialist cannot consider any medical treatment in PCOS patients with anovulation if 
lifestyle intervention is not practiced. In a study by Norman et al.22, they demonstrated that lifestyle 
modification led to increased insulin sensitivity and also resulted in improved ovulation and fertility 
in obese women with PCOS. This approach of lifestyle modification, which includes weight-
reducing diet and exercise, should be the first step in the management of the obese patient with 
PCOS23. 
 
Two excellent review articles were published recently24,25.  In the one review25, the studies by 
Nestler18, Malkawi19 and Sturrock17 were not included in their analysis. In the other review24, the 
study by Nestler18 was not included.  In this review24 the authors included a study by Yarali26 where 
FSH was added, which made the set of data very heterogeneous. Based on the above-mentioned 
facts and the fact that C/C-resistance is a major problem in the handling of the PCOS patient, we 
performed another meta-analysis with more articles to our disposal and according to the selection 
criteria as outlined. For the meta-analysis, we obtained data from four prospective randomised 
double blind trials and two prospective randomised (not double blind) trials. The data on the first 
four articles14,15,16,17 clearly showed a statistical significant effect in favor of ovulation with addition 
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of metformin. When the data of the two prospective randomised articles8,19 were pooled with the 
first mentioned data set it further confirmed the positive effect on ovulation with the addition of 
metformin in the C/C-resistant patient (Figure 3). Although the prospective randomised studies used 
in the meta-analysis are strong pieces of evidence in favor of the use of metformin in C/C-resistant 
patients, we must emphasize the small number of patients in the studies as well as the heterogenous 
set of data. Future randomised control studies should address this defect. It is interesting to note that 
the positive effect with the addition of Metformin in the C/C-resistant patient is further strengthened 
by two cohort studies20,21. 
 
In contrast with the above-mentioned studies where metformin was added only after C/C- resistance 
was observed, Fleming et al.27 performed the only prospective double-blind placebo controlled trial 
where metformin was primarily randomised with placebo in women with oligo-amenorrhoea and 
PCOS. In this study 45 women used metformin and 47 used placebo. Twenty three percent of the 
metformin treated group ovulated and only thirteen percent in the placebo group ovulated. This 
difference was modest, but statistical significant. It is, however, important to note that the dropout 
rate in the metformin group was 30% due to side effects.  The main side effects were nausea and 
gastrointestinal complications.  (See chapter 2, Discussion Metformin) 
 
In a review article by Nestler et al.28 the opinion was expressed that for practical purposes all 
patients should be regarded as insulin resistant. However, if we compare on the one hand the 
significant benefit of the addition of metformin in the C/C-resistant patient with on the other hand 
the results of Fleming et al.27, it will be difficult to conclude that all PCOS women should receive 
metformin to achieve ovulation. It is our opinion that the side effects must be taken in consideration 
before prescribing the drug. A percentage of patients will definitely benefit by simple lifestyle 
measures as well as C/C alone as primary ovulation induction method.  
 
Based on our study it can be concluded that metformin is highly effective in achieving ovulation in 
the C/C-resistant patient. We also recommend that all obese PCOS patients seeking fertility help 
should be guided using a lifestyle modification program that should include weight-reducing diet 
and exercise22,23. When this goal is achieved the patient can be started on C/C and if C/C-resistance 
is present, metformin can be added to achieve ovulation. 
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TABLE 1.  Validity criteria and scoring for methodology assessment of studies 
Category Score Method 
A.  Randomization 3 
 
2 
1 
Randomised by central means (telephone and pharmacy) or sealed 
accounted envelopes. 
Alternating numbers. 
Methods not described. 
B.  Group Demographics 2 
1 
Demographics comparable. 
Demographics not described. 
C.  Placebo use 2 
1 
Placebo or other treatment used in control group. 
No placebo or other treatment. 
D.  Follow-up 2 
1 
Outcome data for primary analysis complete. 
Outcome data incomplete. 
E.  Co-intervention 2 
 
1 
Other than for use of treatment versus control, protocol involved same 
drugs. 
Difference in protocols that may lead to contaminated results. 
F.  Patient and cycle differentiation 3 
2 
1 
Only first treatment cycle included. 
Patients included for more than 1 cycle. 
Cycles and patients not differentiated. 
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TABLE 2.  Validity criteria score 
Study Score Randomization Demo-
graphics 
Placebo/ 
Other 
Follow-
up 
Co-
intervention 
Cycles Total 
Batukan 50% 0 1 1 2 1 2 7 
Parsenezhad 57% 0 2 1 2 1 2 8 
Nestler 85% 2 2 2 2 2 2 12 
Malkawi 78% 2 1 2 2 2 2 11 
Hung Yu Ng 92% 3 computer/ 
sealed envelopes 
2 2 2 2 2 13 
Sturrock 85% 2 2 2 2 2 2 12 
Kocak 92% 3 sealed 
envelopes 
2 2 2 2 2 13 
Vandermolen 92% 3 computer 
generated 
2 2 2 2 2 13 
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FIGURE 1. 
Group 1: Four trials where the addition of metformin was randomised in a prospective double-
blind placebo controlled fashion in the C/C resistant patient 
 
 
 
 
 
 
 
 
n/N = the number of women where ovulation induction was achieved / the total number 
n/N = the number of women where ovulation induction was achieved / the total number 
of women in the group 
 
  
- 61 - 
 
FIGURE 2.  
Group 2: Two trials where the addition of metformin was prospectively randomised in the C/C 
resistant patient 
 
 
 
 
 
 
 
 
 
n/N = the number of women where ovulation induction was achieved / the total number 
of women in the group 
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FIGURE 3. 
Group 3:    Pooled data of group 1 and 2. 
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CHAPTER 4 
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EVALUATING THE EQUIVALENCE OF CLOMIPHENE CITRATE WITH AND 
WITHOUT METFORMIN IN OVULATION INDUCTION IN PCOS PATIENTS: A 
RANDOMISED CONTROLLED TRIAL 
 
4.1 INTRODUCTION 
Polycystic ovary syndrome is one of the most common endocrinopathies, affecting 5-10% of 
women of reproductive age1. Various criteria have been proposed for the diagnosis of PCOS which 
hampered research into this common disorder2,3.  Fortunately, in 2003 a joint consensus meeting 
between the American Society of Reproductive Medicine and the European Society of Human 
Reproduction and Embryology proposed a unifying definition4.  Oligo-anovulation due to ovarian 
dysfunction continues to be the pivotal feature that makes this syndrome the major cause of 
anovulatory infertility in developed countries5. 
 
Clomiphene citrate(C/C) was the first agent used in experiments for ovulation induction in 
oligomenorrheic women6.  For many years it was and may still be the first therapeutic option 
managing anovulatory infertility.  The treatment with C/C in anovulatory PCOS women is related to 
an ovulation rate of 60-85% and a pregnancy rate of 30-40%7. Reasons for this discrepancy may be 
due to the anti-oestrogenic effect of C/C acting at both an endometrial and ovarian level, in addition 
to the development of a hostile cervical mucus8. 
 
The addition of metformin to C/C in C/C-resistant women significantly improves the ovulation rate.  
The meta analysis in a Cochrane review reported a significant benefit for metformin compared to 
placebo for ovulation in anovulatory women with PCOS9.  Another metanalysis showed a 
significant positive effect of metformin when added to C/C in the C/C-resistant PCOS patient10.  
The first head to head study comparing C/C with metformin has recently been published11.  It 
demonstrated that both medications are highly effective for ovulation induction, but that metformin 
use results in higher cumulative pregnancy rates.  However, this study was restricted to young, lean 
PCOS women without glucose tolerance problems or tubal or male factors. 
 
From the available data it remain unclear whether the addition of metformin to C/C is superior to 
C/C alone as a primary induction agent and where metformin should be introduced in ovulation 
induction protocols in the PCOS patient. 
 
The aim of this study was to evaluate the benefit of metformin if added to C/C in a primary 
ovulation induction protocol in comparison to C/C alone.   
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4.2 MATERIALS AND METHODS 
4.2.1 Patients 
This study was approved by the Ethical Committee of Stellenbosch University at Tygerberg 
Academic Hospital (2003/013). Informed consent was obtained from each patient involved.  A total 
number of 107 patients diagnosed with PCOS were enrolled for ovulation induction in a treatment 
period of 15 months.  The inclusion criteria required that all couples needed to present with a 
history of infertility for at least 18 months.  The diagnosis of PCOS was based on the recent 
Rotterdam consensus statement.  All patients had a complete infertility and PCOS work up 
consisting of weight and body mass index (BMI), hysterosalpingogram(HSG), basal hormonal tests 
(FSH, LH, TSH, Prolactin, 17-OH Progesterone, DHEAS, SHBG, Testosterone, fasting insulin, 
fasting glucose and fasting lipid profile.), semen analysis on the husband and where indicated a 
diagnostic hysteroscopy and laparoscopy was performed.  Patients with known tubal factors, 
azoospermia or severe oligoteratozoospermia were excluded from this study. The Tygerberg strict 
criteria was used to evaluate the sperm morphology and the rest of the semen parameters according 
to the WHO manual 199912. 
 
All obese patients (BMI >25) were informed to loose at least 5% of their weight and to participate 
in exercise for at least 40 minutes per day 3 days per week.  They were motivated regarding short-
term positive impact of weight loss regarding ovulation induction and long term benefits on 
development of Diabetes Mellitus, ischaemic heart disease and lipid abnormalities. 
 
4.2.2 Study 
This was a prospective randomised controlled trial of 107 consecutive PCOS patients. Inclusion 
criteria: all patients diagnosed with PCOS were included.  The diagnosis of PCOS was according to 
the recent Rotterdam consensus statement. Exclusion criteria: patients known with tubal factors, 
azoospermia, severe oligoterato-zoospermia or any other reason for anovulation or hirsutism were 
excluded. 
 
The randomization was computer generated and patients were randomised into two groups.  Group 
A received pre treatment with metformin 850mg twice a day for at least 6 weeks before C/C was 
added and the metformin was used throughout the study period.  Group B received C/C without pre 
treatment of metformin. In both groups C/C was given at a starting dose of 50mg day 4-8 and 
increase with increments of 50mg to a maximum of 150mg if no response was achieved.  We did 
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not pre-treat patients in group B with placebo.  This is a definite shortcoming of the study.  
However, the drop-out rates in the 2 groups were similar. 
 
The patients were followed up with transvaginal ultrasound to record follicular growth and 
endometrial response.  Day 21 progesterone was drawn to confirm ovulation.  (Figure 1) 
 
4.2.3 Statistical Analysis 
An intention to treat analysis was performed for the primary outcome ovulation success.  
 
For a full intention to treat analysis, we have to include all randomised women, those who were lost 
to follow-up too. 
 
A secondary analysis of the patient factors associated with ovulation was also performed. The 
Mann-Whitney test was used for the comparison of the ovulation and non-ovulation groups with 
respect to characteristics such as 17OH Progesterone, Testosterone, SHBG and fasting insulin. For 
the significant factors identified in this analysis a further logistic regression analysis was done of 
ovulation success on the specific factor with adjustment for a treatment effect.  
 
4.3 RESULTS 
The results are presented in different sections. The first part is the primary analysis to test the 
equivalence in ovulation between the two treatment arms. The second part is a secondary analysis to 
assess the possible association between the different factors and ovulation.  
 
4.3.1 Intention to treat analysis (Table 1) 
The intention to treat analysis, which include the patients who were lost to follow up too, was 
performed. (Table 1) 
 
In the M+C/C arm 34/52 (65.4%) achieved ovulation compared to 36/55 (65.5%) in the C/C alone 
arm. The estimated mean different is 0% with 90% confidence intervals -16% to 18%. Since this 
interval does not fit within the equivalence interval (-10% to 10%) we cannot conclude equivalence.  
 
The intention to treat analysis strengthens the conclusion that metformin should not be added to C/C 
since the ovulation rates achieved, as intended when randomizing the women in the trial, were 
identical. 
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4.3.2 Primary outcome (Table 2) 
The ovulation rate achieved in women in the M+C/C arm was 34/42 (81%) compared to 36/48 
(75%) in the C/C arm. (Table 2) The treatment effect ((M+C/C) –C/C) is 6% with 90% confidence 
interval of -9% to 20%.  Since this interval does not fit within the equivalence interval we cannot 
conclude equivalence.  Using the confidence interval we can also not conclude superiority of 
metformin and C/C versus C/C alone since the interval spans 0%, the reference value of no 
difference between the arms. In this analysis, the patients who were lost to follow-up were 
excluded. 
 
4.3.3 Patient Characteristics 
In the metformin + C/C group, 42/52 women had a positive outcome (81%) compared to 48/55 in 
C/C group (87%).  The total loss to follow-up was 17 patients (16,3%).  10 patients were lost to 
follow-up in group A, and 7 patients were lost to follow-up in group B. 
 
Since the duration of the treatment is different with M+C/C being much longer one would expect 
this arm to have a higher dropout. The follow-up achieved was similar in both groups.  The baseline 
characteristics in the two arms of the study were similar.  There were 2 women diagnosed with 
pregnancy before follow-up. These two women received C/C 50mg and did not attend their first 
follow-up.  They were regarded as having had a successful ovulation at 50mg. 
 
4.3.4 Comparison of the dosage level of ovulation success or failure (Table 3) 
The estimated treatment effect by C/C dosage show an increased effect by dose. However the 
sample size within each dose is small and a test for a dose by treatment effect is not significant, 
p=.414. The 90% confidence intervals for the estimated treatment effect is also given for 
completeness. (Table 3) 
 
4.3.5 Determinants of ovulation 
The descriptive characteristics of the factors considered as possible determinants for ovulation is 
mentioned in the Materials and Methods section. These factors were weight and body mass index 
(BMI), hysterosalpingogram(HSG), basal hormonal tests (FSH, LH, TSH, Prolactin, 17-OH 
Progesterone, DHEAS, SHBG, Testosterone, fasting insulin, fasting glucose and fasting lipid 
profile.), and a semen analysis. 
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The Mann Whitney test was used to do a non-parametric comparison of ovulating versus non-
ovulating women, for each of the factors, to assess if any of these factors were associated with 
ovulation outcome. 
 
From this analysis, weight (p=.021), DHEAS (p=.05), 17OH-progesterone (p=.027), SHBG 
(p=.036) and BMI (p=.009) were significant factors. Marginal risk factors for ovulation outcome 
were height (p=.097) and fasting glucose (p=.085). 
 
To further evaluate the factors affecting ovulation, a logistic regression model was used where the 
factors found above were evaluated with an adjustment for a treatment effect.  The variable SHBG 
is a significant factor after adjustment for treatment with odds ratio (OR) 1.04; 95% CI :1.0 to 1.07; 
p=.049. It is positively associated with ovulation. 
 
The variables 17OH-progresterone (OR=.82; 95%CI: .67 to .99; p=.043), BMI (OR=.90; 95%CI: 
.82 to .98; p=.0.018) and weight (OR=.97; 95%CI: .94 to 1.0; p=.049) were also significant factors 
after adjustment for treatment. These factors were negatively associated with ovulation. In this 
study all women with a BMI below 27 kg/m2 achieved ovulation irrespective of treatment received. 
 
The variables DHEAS and fasting glucose were no longer significant factors after adjustment for 
treatment. 
 
4.4 DISCUSSION 
In the treatment of women with PCOS who wants to get pregnant our study could not establish 
equivalence or find any benefit of adding metformin to C/C comparing to the standard treatment 
with C/C alone in women receiving these options as primary induction choice. We found no 
significant differences in outcome of ovulation induction in the two different groups studied.  We 
also observed no difference in the discontinuation rate between the two groups. 
 
In addition to the results of our study, four prospective randomised controlled trials were recently 
published11,13,14,15.  The primary aim of these studies was to compare C/C with metformin alone or 
in combination when studied as primary ovulation induction agents in women with PCOS. In the 
first study by Moll et al13, they prospectively randomised 228 women. The primary aim of this 
study was the ovulation rate. The ovulation rate in the metformin and C/C group was 64% 
compared with 72% in the placebo and C/C group which was not statistical significant. There was 
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no difference in the pregnancy rates or the abortion rates of the 2 groups and the mean BMI was 28 
in both groups.  
 
In the second study by Legro et al14, 626 PCOS patients were randomised. The primary outcome of 
their study was live birth rates. They concluded that C/C (22,5%) is superior to metformin (7,2%) 
but similar to the combination group (26,8%) in achieving live birth rates. As a secondary outcome 
ovulation was addressed, again metformin alone performed significant worse than C/C alone or the 
combination of C/C and metformin. They did not observe any difference in the abortion rates 
between the 3 groups and observed a significant better live birth rate if the BMI is less than 30 
regardless the treatment option used. 
 
In the third study by Neveu et al15, they prospectively randomised 154 patients with PCOS. In this 
study they observed a significant better ovulation rate when on metformin alone (75,4%) compare 
to C/C alone(50%).  In the combination group of C/C and metformin the ovulation rate (63,4%) was 
not significantly different to the metformin alone but significant better than the C/C alone. 
However, pregnancy rates were equivalent in the three groups. They also observed a better 
ovulatory response in the women with a lower BMI in the C/C group and patients with a BMI of 
27-35 responded better to metformin for ovulation induction. The mean BMI of the study was 31. 
This study had a better ovulation rate in the metformin and the combination group, but no 
difference in pregnancy rates between the three groups.  These three authors concluded that it is not 
beneficial to add metformin to C/C in primary ovulation induction protocols.  
 
In the fourth study by Palombo et al11, they included 100 PCOS women.  In this study, they too did 
not observe any difference between the metformin group and the C/C group regarding the ovulation 
rates.  However, when analyzing the data regarding cumulative pregnancy rates there were a 
significant better rate 15,1% in the metformin group versus a 7,2% in the C/C group. It is however 
important to note that women with a BMI>30 were excluded from this study and they concluded 
that metformin was superior to C/C in achieving a live birth. 
 
In one of the first studies to address this topic, Nestler et al16 conducted a multicenter study. In this 
study they studied 61 obese PCOS women. They concluded that spontaneous ovulation induced by 
C/C may be increased in obese women with PCOS by decreasing serum insulin concentrations with 
metformin.  This was not a prospective randomised control trial and it was also a very small study. 
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In our study, we prospectively randomised 107 patients and 17 (16,3%) patients were lost to follow 
up.  In the study by Moll et al13, they lost 63 (27,6%) patients to follow up.  In their study more 
patients were lost in the metformin group, which might have been due to the side effects. In 
contrast, in our study a similar number of women were lost to follow up in the two groups studied.  
 
If we look at the primary characteristics of the two groups in our study, no significant differences 
were noted.  The combination of metformin and C/C had a 6% better ovulation rate as C/C alone.  
This trend may only be a chance effect or may be significant if the numbers were more. 
 
In the study by Moll et al13 a similar outcome to our study was observed, however Legro et al14 
observed a poorer ovulation rate in the metformin group versus C/C alone or the combination of the 
two drugs.  In contrast, Neveu et al15 observed a poorer ovulation rate in the C/C alone group versus 
the metformin or metformin and C/C combination. However, when these authors commented on 
live birth rates, Moll et al13 and Neveu et al15 documented no difference between the two groups, but 
Legro et al14 observed a significant lower rate in the metformin group versus the C/C alone or 
combination group. These authors concluded that metformin should not be added to C/C in primary 
ovulation induction regimens.  
  
In the secondary analysis of our study, we observed that all patients ovulated with a BMI<27. With 
a BMI>27 there was no difference in ovulation between C/C alone or metformin and C/C. Legro et 
al14 observed a significantly higher rate of live births in women with a BMI less than 30 when 
compared to those with a BMI more than 30. However, in the study by Neveu et al15, they observed 
a better outcome when metformin was added in the more obese group, BMI 27-35. This improved 
outcome on metformin in the more obese patients was also observed in the study by Nestler et al16. 
In the study by Palombo et al11 they unfortunately excluded women with a BMI more than 30.  
 
As part of the secondary analysis of our study, the Mann Whitney test was performed to test for an 
association of any of the characteristics and unsuccessful ovulation.  From this analysis we can 
extrapolate that weight/BMI (P=.009) was the major predictive factor. This is a very important 
finding and supports current literature to optimize the BMI first, loose weight if needed, before 
commencing with any ovulation induction regimen17. 
 
Other important factors observed in the current study were SHBG (sex hormone binding globulin) 
P=.036 and 17hydroxy progesterone (17OH Progesterone) P=.027. The variable SHBG was a 
significant factor and positively associated with ovulation. The physiological effect of SHBG is a 
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lowering of the free androgen index. This may lead to an improved ovulation outcome. In a study 
by Ghazeeri et al18, rosiglitazone was administered to 25 obese, C/C-resistant, PCOS women who 
desired pregnancy. They observed a significant improvement in ovulation rates when rosiglitazone 
was added to C/C in this study. One of the important findings was a significant rise in SHBG in the 
group of women treated with rosiglitazone. Our study confirms this finding of improved ovulation 
rates with a higher SHBG level. Several other investigators have similarly observed an increase in 
SHBG and a decrease in testosterone and androgenicity with improved conception rates in patients 
with weight loss19,20.   In a recent Cochrane review it was concluded that metformin significantly 
reduced androgen levels9.  This subgroup of women with PCOS and high androgen levels may have 
an improved outcome when metformin is added for ovulation induction.  However, more data are 
required before it can be concluded that this subgroup is a definite indication for the use of 
metformin.  The variable 17OH-progesterone was also a significant factor and was negatively 
associated with ovulation. The factors fasting glucose and insulin had no positive or negative 
association with ovulation.  
 
Based on the results of this trial, we cannot exclude the possibility that the addition of metformin 
may lead to an increase in the ovulation rate of 6%. This 6% may be a chance effect or it might 
have been that if the study was bigger, the difference may have been significant. The sample size 
(n=107) was the biggest limitation of our study. However, two other prospective randomised 
control trials had similar outcomes to our study13,14 regarding ovulation outcome. All three 
authors13,14,15 concluded that metformin should not be added in primary induction protocols. In a 
recent meta-analysis, it was found that the addition of metformin is beneficial when added to C/C in 
the C/C-resistant PCOS women10. Based on the results of our study and the trials discussed, we 
conclude that metformin should not be added to C/C as a primary method for ovulation induction in 
women with PCOS. The addition of metformin is advised in the C/C-resistant PCOS women. 
However, it is of utmost importance that all obese PCOS women should first be placed on an active 
exercise and weight loss programme before any treatment is offered. 
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FIGURE 1:  Study Flowchart 
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TABLE 1.  Intention to treat analysis. 
Table 1 M+C/C* C/C** TOTAL 
Ovulation 34 36 70 
(column%) (65.38%) (65.45%) (65.42%) 
Non-ovulation 18 19 37 
(column%) (34.62%) (34.55%) (34.58%) 
TOTAL 52 55 107 
(column%) (100.00%) (100.00%) (100.00%) 
*M = Metformin 
**C/C = Clomiphene Citrate 
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TABLE 2:  Ovulation rates in the two treatment arms  (Unpaired Samples) 
 Sample M+C/C Sample C/C Total 
Number with ovulation 34 36 70 
Number without ovulation 8 12 20 
Sample Size 42 48 90 
Proportions 0.810 0.750 
Difference 0.060 
 
90% Confidence Interval for the difference    -0.087   to    0.199  Recommended (Newcombe) Method 
Standard Error of difference    0.087  Normal Value    1.650 
 
M=Metformin 
C/C=Clomiphene citrate 
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TABLE 3: Ovulation outcome:  Dosage comparison 
Dose M+C/C  (%) C/C (%) Difference 90% CI(lower to upper) p-value 
50mg 20/27 (74)   18/23 (78) 4 -31 to 19 .776 
100mg 11/12 (92)   11/14 (79) 13 -20 to 49 .566 
150mg 3/3 (100) 7/11 (64) 36 -22 to 77 .332 
All 34/42 (81) 36/48 (75) 6 -9 to 20 .592 
 
The estimated treatment effect by C/C dosage show an increased effect by dose. However the 
sample size within each dose is small and a test for a dose by treatment effect is not significant, 
p=.414. The 90% confidence intervals for the estimated treatment effect is also given for 
completeness. 
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CHAPTER 5 
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HOW DO WE DEFINE MALE SUBFERTILITY AND WHAT IS THE PREVALENCE IN 
THE GENERAL POPULATION? 
 
5.1 INTRODUCTION 
Several semen parameters are used to discriminate the fertile male from the sub-fertile male.  The 
most widely used parameters are sperm concentration, motility, progressive motility and sperm 
morphology.  Of these parameters, the sperm morphology is the single indicator most widely 
debated in the literature.  A large number of classification systems have been used to describe 
which factors constitute a morphologically normal/abnormal spermatozoon.  The most widely 
accepted classification systems for sperm morphology are World Health Organization (WHO) 
criteria of 1987 and 19921,2 and Tygerberg strict criteria, now also used by the WHO since 1999.3-6 
 
Although there is a positive correlation between normal semen parameters and male fertility 
potential, the threshold values for fertility/sub-fertility according to WHO criteria1,2 are of little 
clinical value in discriminating between the fertile and sub-fertile male.7-11  If these criteria were 
applied, a great number of fertile males (partners having had pregnancies shortly before, after, or at 
the time of a spermiogram) were classified as sub-fertile.  The predictive values of sperm 
morphology using strict criteria in in vitro fertilization (IVF) and intrauterine insemination (IUI) 
have been reviewed recently and proved to be useful.12,13  Much less has been published on the use 
of this criterion regarding in vivo fertility. 
 
5.2 AIM 
In this chapter we will evaluate the classification systems for semen parameters after review of the 
literature published in English on semen parameters and in vivo fertility potential.  We will also use 
data from the literature to establish fertility/sub-fertility thresholds for semen parameters and the 
WHO 1999 guidelines.3-6  These thresholds should be of clinical value and useful when assessing 
male fertility potential for in vivo conditions in order to identify those males with a significantly 
reduced chance of achieving success under in vivo conditions.  In general there is also quite a poor 
level of understanding and evidence regarding the profile of the semen analysis of the general 
population. 
 
Therefore, we believe that possibly the best reference group to study the semen profile in a general 
population is the semen of partners of women who have been diagnosed to have chronic 
anovulation/PCOS.  
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5.3 WHO CRITERIA OF 1987 AND 1992 AND MALE FERTILITY POTENTIAL 
The semen analysis is used in clinical practice to assess the male fertility potential.  To be of 
clinical value the methods used for semen analysis should be standardized and threshold values for 
fertility/sub-fertility should be calculated for the different parameters used in standard semen 
analysis. 
 
Because there are so many different methods for semen evaluation, it would be difficult to 
standardize the methods used in semen analysis.  This applies especially to the assessment of sperm 
morphology.  The two classification systems most widely accepted are the WHO1,2 and the 
Tygerberg strict criteria.3-6  Various methodological problems concerning sperm morphology have 
been identified.  The variants among different methods of morphology assessment have been shown 
by Ombelet et al.14-16 and others17,18 and they recommended standardization of semen analysis 
methodologies.  Some authors recommend that laboratories should adopt the accepted standards 
such as those proposed by the WHO.17,18  Another problem identified is the variation in intra-and 
inter-individual and inter-laboratory sperm morphology assessment.18,19  This problem could be 
addressed by using the Tygerberg strict criteria.  
 
Menkveld et al. showed that comparable and reliable results between and within observers could be 
obtained when using this method.19  Franken et al. delivered dedicated work on continuous quality 
control programs for strict sperm morphology assessment and showed that consistent reading could 
be achieved and thus urged for global quality control measurements in andrology laboratories.20,21  
Cooper et al.18 also urged for standardization of such quality control programs and that quality 
control centres should reach agreement with each other. 
 
Previous WHO thresholds of 50% and 30% for sperm morphology were empiric values and not 
based on any clinical data.  Several authors found these values to be of little or no clinical 
value.7,9,10   These studies did, however, find a positive correlation between the high proportion of 
morphologically normal sperms and the increased likelihood of fertility and/or pregnancy.  Other 
studies confirmed this correlation.22-25 
 
Van Zyl et al.25 were the first to show a faster than linear decline in fertilization rate when the 
proportion of normal forms dropped to less than 4%.  Eggert-Kruse et al.23 found a higher in vivo 
pregnancy rate for higher percentage normal forms at thresholds of 4, 7 and 14% using strict criteria 
for morphology assessment.  Zinaman et al. confirmed the value of sperm morphology (strict 
criteria) by demonstrating definite decline in pregnancy rates in vivo, when the normal morphology 
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dropped below 8% and sperm concentration below 30x106/ml.26  In a study performed by Slama et 
al.27, measuring the association between time to pregnancy and semen parameters, it was found that 
the proportion of morphologically normal sperm influenced the time to pregnancy up to a threshold 
value of 19%.  This value is somewhat higher than that calculated in other studies. 
 
5.4 THE USE OF SEMEN PARAMETERS IN IVF AND IUI PROGRAMS 
The percentage of normal sperm morphology (strict criteria) has a positive predictive value in IVF 
and IUI programs.  Normal sperm morphology thresholds produced positive predictive values for 
IVF success when using the 5% and the 14% thresholds, respectively, with the overall fertilization 
rate and overall pregnancy rates significantly higher in the group with normal morphology bigger or 
equal than 5% as compared with the smaller than 5% group.12  A meta-analysis of the data on IUI 
programs showed a higher pregnancy rate per cycle in the group with normal sperm morphology of 
equal to or bigger than 5%.  In the group with normal sperm morphology less than 5%, other semen 
parameters proved to be predictive IUI success.13  In the IUI analysis, motility28, total motile sperm 
count29 and concentration30 also played a role in some of the studies evaluated, whilst others31 stated 
that sperm morphology alone was enough to predict the prognosis.  Because of the high cost of 
assisted reproduction, males with good or reasonable fertility potential under in vivo conditions 
should be identified on the basis of semen quality.  Conversely, males with a poor fertility potential 
should be identified and introduced to assisted reproduction programs. 
 
5.5 FERTILITY/SUBFERTILITY THRESHOLDS FOR SPERM MORPHOLOGY 
USING TYGERBERG STRICT CRITERIA, SPERM CONCENTRATION AND 
SPERM MOTILITY/PROGRESSIVE MOTILITY 
In an effort to establish fertility/sub-fertility thresholds for the abovementioned parameters we 
identified four articles in the published literature.  It is our opinion that these articles constitute a 
representative sample of studies published on the predictive value of sperm morphology, sperm 
concentration and motility/progressive motility for in vivo fertility/sub-fertility.  These articles 
compared the different semen parameters of a fertile and a sub-fertile group.  They used either the 
classification and regression tree (CART) analysis or the receiver operating characteristic (ROC) 
curve analysis to estimate thresholds for the different semen parameters.  The ROC curve was also 
used to assess the diagnostic accuracy of the different parameters and their ability to classify 
subjects into fertile and sub-fertile groups.   
 
Using ROC curve analysis, Ombelet et al.32 calculated the following thresholds: proportion normal 
morphology 10%, proportion normal motility 45% and normal sperm concentration 34x106/ml.  The 
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sperm morphology was shown to be the best parameter with the highest prediction power (area 
under curve or AUC 78%).  Much lower thresholds were calculated using the 10th percentile of the 
fertile population, these thresholds being 5% for normal morphology, 28% for motility and 
14.3x106/ml for sperm concentration (table 1 and 2).32 
 
Günalp et al.33 also calculated thresholds using ROC curve analysis.  The thresholds were 
proportion normal morphology 10%, proportion normal motility 52%, proportion progressive 
motility 42% and sperm concentration 34x106/ml.  The two parameters that performed best were 
progressive motility (AUC 70.7%) and morphology (AUC 69.7%).  Assuming 50% prevalence of 
sub-fertility in the population, the authors used the positive predictive value as indicator to calculate 
a lower threshold for each parameter.  Values of 5% for proportion normal morphology, 30% for 
proportion normal motility, 14% for proportion progressive motility and 9x106/ml for sperm 
concentration were calculated (Tables 1 and 2).33 
 
In the most recent article of the four, Menkveld et al.34 found much lower thresholds than the others.  
Using ROC curve analysis, the following thresholds were calculated: 4% for normal morphology 
and 45% for normal motility.  The morphology again showed a good predictive value with an AUC 
of 78.2%.  Although a threshold for sperm concentration was not calculated (a sperm concentration 
smaller than 20x106/ml was used as inclusion criterion), the authors proposed that the cut-off value 
of 20x106/ml could be used with confidence, based on the resultant lower 10th percentile of the 
fertile population.  Adjusted cut-off points calculated on the assumption of 50% prevalence of male 
sub-fertility were as follows: 3% for proportion normal morphology and 20% proportion normal 
motility (Tables 1 and 2).34   
 
In the fourth article by Guzick et al.,35 the authors used the CART analysis and calculated two 
thresholds for each semen parameter which allowed for designation in three groups, namely normal 
(fertile), borderline and abnormal (sub-fertile).  The normal (fertile) group had values greater than 
12% for morphology, greater than 63% for motility and higher than 48x106/ml for sperm 
concentration.  The abnormal (sub-fertile) group had values lower than 9% for morphology, lower 
than 32% for motility and lower than 13.5x106/ml for sperm concentration. 
 
In these four articles the predictive power of the different parameters were calculated as its AUC 
using the ROC curve.  The AUC for sperm morphology ranged from 66-78.2%, confirming the high 
predictive power of sperm morphology.  In fact, it had the best performance of the different semen 
parameters in two articles.32,35  The threshold calculated in these two articles were 10% and 9% 
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respectively while Günalp et al.33 calculated a threshold of 12% using sensitivity and specificity to 
analyze their data and the fourth study calculated a 4% predictive cut-off point value.  Although 
sensitivity and specificity for the values are relatively high, the positive predictive values are not.  
This will result in classifying fertile males as sub-fertile, therefore, probably leading to a degree of 
anxiety and unnecessary and costly infertility treatment.  A second and much lower threshold was 
calculated in three of the four articles.  Ombelet et al.32calculated their second and much lower 
threshold by using the 10th percentile of the fertile population while Günalp et al.33 screened the 
population with the positive predictive value as indicator and Menkveld et al.34 assumed a 50% 
prevalence of sub-fertility in their study population.  The lower threshold ranged from 3 to 5% 
(Table 2).  These lower thresholds have a much higher positive predictive value than the higher 
thresholds with the negative predictive value not much lower. 
 
We suggest that the lower threshold should be used to identify males with the lowest potential for a 
pregnancy under in vivo conditions.  Values above the lower threshold should be regarded as 
normal.  These findings are in keeping with previous publications by Coetzee et al.12 (IVF data) and 
Van Waart et al.13 (IUI data) which showed a significantly lower chance of successful pregnancies 
in males with normal morphology below their calculated thresholds. 
 
The higher threshold values for percentage motile sperm as calculated in the four articles (using 
ROC curve or CART analysis) ranged from 32 to 52% while the lower threshold values ranged 
from 20 to 30%.  Motility also had a high predictive power with an AUC of between 59 and 79.1%.  
Günalp et al.33 calculated thresholds for progressive motility: a higher threshold of 42%, using the 
ROC curve, and a lower threshold of 14% with a positive predictive value as indicator.  In this 
study, progressive motility proved to be a marginally better predictor of sub-fertility than sperm 
morphology with AUC values of 70.7 and 69.7%, respectively.33  Montanaro Gauci et al.28 found 
percentage motility a significant predictor of IUI outcome.  The pregnancy rate was almost three 
times higher in the group with motility bigger than 50% as compared with the group with motility 
less than 50%. 
 
The higher threshold values for sperm concentrations calculated by Ombelet et al.,32 Günalp et al.33 
and Guzick et al.35 ranged from 13.5x106/ml to 34x106/ml while the lower threshold values ranged 
from 9x106/ml to 14.3x106/ml.  An AUC value of between 55.5 and 69.4% served as confirmation 
of the predictive power of this parameter.  Although Menkveld et al.34 did not calculate a threshold 
value for sperm concentration (because values of less than 20x106/ml served as inclusion criteria in 
their study), they suggested a threshold value of 20x106/ml to be used with confidence because it 
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did not influence the results from their fertile population.  The clinical value of motility and sperm 
concentration serve as confirmations of findings reported in numerous other publications.7,8,11,22-24 
 
Although the different parameters had good predictive power, independent of each other, the 
clinical value of semen analysis increased when the parameters were used in combination.  Ombelet 
et al.32 found that the differences between the fertile and sub-fertile populations only became 
significant, when two or all three semen parameters were combined.  Bartoov et al.36 concluded that 
the fertility potential is dependent on a combination of different semen characteristics.  Eggert-
Kruse et al.23 found a significant correlation between the three parameters reviewed in their study.  
Although the different semen parameters show good individual predictive power, the clinical value 
of semen analysis increases when the parameters are used in combination.  We, therefore, suggest 
that no parameter should be used in isolation, when assessing male fertility potential.  The lower 
thresholds as discussed in this chapter have a much higher positive predictive value and a high 
negative predictive value.  Therefore, we suggest that these lower thresholds should be used in 
identifying the sub-fertile male.   
 
As suggested by WHO in 1999, each group should develop their own thresholds based on the 
population they are working in.  Each laboratory should establish these thresholds if possible.  It 
seems as if the sperm morphology threshold of 0-4% normal forms indicates a higher risk group for 
sub-fertility and fits the IVF and IUI data calculated previously.12,13  The four articles discussed in 
the latter half of this chapter32-35 showed the same trends and can serve as guidelines to distinguish 
fertile from sub-fertile males. 
 
As far as concentration and motility are concerned, the thresholds are not clear, but a concentration 
lower than 10million/ml and a motility lower than 30% seem to fit the general data.32-35  However, 
more, preferably multi-centre, studies are needed to set definitive thresholds. 
 
5.6 SEMEN PROFILE OF THE GENERAL POPULATION: PARTNERS OF WOMEN 
WITH CHRONIC ANOVULATION 
In general there is quite a poor level of understanding and evidence regarding the profile of the 
semen analysis of the general population. Many male populations have been proposed to be the 
mirror image of the semen analysis of the general population. Using donors of a semen donation 
program for normality is certainly not the best option since this population is positively biased for 
fertility. Army recruits are biased by age. Husbands of tubal factor patients can be biased by a 
positive history of infection (tubal factor due to pelvic infection) or a good fertility history (women 
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with tubal sterilization). Therefore, we believe that possibly the best reference group to study the 
semen profile in a general population is the semen of partners of women who have been diagnosed 
to have chronic anovulation/PCOS. 
 
Two different studies, one retrospective and one prospective evaluating the semen analysis of the 
partners of women presenting with anovulation were selected. 
 
5.6.1 Retrospective study of partners of women presenting with chronic anovulation (> 35 
days) at Tygerberg Fertility Clinic 
Included in this study were all male partners of patients diagnosed as anovulatory, at the Tygerberg 
Fertility Clinic. The methods used to examine the semen were according to the WHO guidelines6 
and for sperm morphology Tygerberg strict criteria was used.3,4,6  The laboratory personnel initially 
evaluated all slides and each slide was then evaluated by one observer (TFK) according to strict 
criteria. Sixty-two samples were eventually selected and included in the study (Table 3). 
 
5.6.2 A prospective study of partners of women presenting with PCOS at the Tygerberg 
Fertility Clinic 
Tygerberg Fertility Clinic conducted a study on patients with PCOS. The patients were diagnosed 
with PCOS according to the recent Rotterdam consensus statement.37 The aim of this study is to 
establish factors influencing ovulation induction in this group. 
 
The semen of the partners of all these women was examined. The methods used to examine the 
semen were according to the WHO guidelines6 and for sperm morphology Tygerberg strict criteria 
was used.3,4,6  The lab personnel initially evaluated all slides and all P-pattern slides were evaluated 
by one observer (TFK) (Table 4). The thresholds used for subfertility are those suggested by Van 
der Merwe et al.38 in their recent review:  0-4% normal forms;  <30% motility;  <10mill/ml and 
outlined in the first section of this chapter. 
 
5.7 DISCUSSION 
In the two studies (Table 3, retrospective; Table 4, prospective) ±50% of patients had a normal 
semen analysis.  The most common single abnormality was that of teratozoospermia (25.8% 
retrospective, and 27.8% prospective).  Azoospermia occurred in 1.4% to 4.8% respectively of 
patients with triple parameter defects in only 1.4% to 3.2% of cases (Tables 3 and 4). 
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The thresholds as calculated above were used in a group of anovulatory women.  These thresholds 
give a reflection of the prevalence of male factor infertility in the general population.  It is 
interesting to note that in both the retrospective and prospective studies the prevalence of 
teratozoospermia (<4% normal morphology) was 25.8% to 27.8% making it the most common 
defect in this group.  About 50% of all the male patients had normal semen parameters based on 
these two studies by using the suggested thresholds as calculated based on the four articles 
discussed.32-35,38 
 
It is also important to note that in PCOS patients the clinician needs to take into consideration that 
not only anovulation needs attention, but also that in up to 50% of these patients the male factor 
also needs attention to assist in achieving a successful outcome in these couples.  These lower 
thresholds is first of all not absolute, but a continuum guiding the clinician to respond to a semen 
analysis.  The golden rule is to repeat an abnormal semen analysis four weeks after the first 
abnormal evaluation to ensure that the correct approach will be followed.  If again abnormal, a 
thorough physical examination should be performed and the necessary treatment offered.  In the 
case of PCOS, the female factor (anovulation) should obviously be corrected starting as first line 
approach with weight loss in women with a BMI >25.  Although 50% of these patients had a male 
factor according to the definition used, it is also important to note that only + 5% of these factors 
were serious (azoospermia and the triple parameter defects) with 8-9.7% with a double defect. 
 
To our knowledge this is the first attempt to use the specific suggested lower thresholds to define 
the prevalence of the subfertile male in the general population by using an anovulatory group of 
women.  These thresholds will guide the clinician towards a more directive management where 
indicated. 
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TABLE 1.  Thresholds: fertile vs. subfertile populations studied 
 
Author Morphology 
(%) 
Motility 
(%) 
Progressive 
motility (%) 
Concentration 
(106/ml) 
Guzick et al. 200117 9 32  13.5 
Menkveld et al. 200116 4 45  20 
Günalp et al. 200115 10 52 42 34 
Ombelet et al. 199714 10 45  34 
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TABLE 2:  Possible lower thresholds for the general population to distinguish between 
subfertile and fertile men based on the assumed incidences of subfertile males in their 
populations 
 
Author Morphology 
(%) 
Motility 
(%) 
Progressive 
motility (%) 
Concentration 
(106/ml) 
Menkveld et al. 200116 3 20  20 
Günalp et al. 200115 5 30 14 9 
Ombelet et al. 199714 5 28  14.3 
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TABLE 3.  Retrospective study of partners of women presenting with chronic anovulation (> 
35 days) at Tygerberg Fertility Clinic 
 
  
Number 
 
% of 
patients 
 
 
 
   
Normozoopermia 29 46.7 
   
Sperm abnormality   
   
Single parameter defect   
 Azoospermia 3 4.8 
 Oligozoospermia (O) 3 4.8 
 Asthenozoospermia (A) - 0 
 Teratozoospermia (T) 16 25.8 
 Polizoospermia (P) 2 3.2 
 Immunological factor (I) 1 1.6 
   
Double parameter defect   
 OA - 0 
 OT 4 6.5 
 AT - 0 
 TP 1 1.6 
 TI 1 1.6 
   
Triple parameter defect   
 OAT 2 3.2 
   
Threshold values used   
Concentration/ml = < 10 ml/l   
Motility = < 30%   
Morphology = < 4% normal forms   
(<10mill/ml cut off) 
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TABLE 4.  A prospective study of partners of women presenting with PCOS at the Tygerberg 
Fertility Clinic 
 
  
Number 
 
% of 
patients 
 
 
 
   
Normozoospermia 41 56.9 
   
Sperm abnormality   
   
Single parameter defect   
 Azoospermia 1 1.4 
 Oligozoospermia (O) 1 1.4 
 Asthenozoospermia (A) - 0 
 Teratozoospermia (T) 20 27.8 
 Polizoospermia (P) 3 4.2 
 Immunological factor (I) - 0 
   
Double parameter defect   
 OA - 0 
 OT 1 1.4 
 AT - 0 
 TP 3 4.2 
 TI 1 1.4 
 OP - 0 
   
Triple parameter defect   
 OAT 1 1.4 
   
(<10mill/ml cut off) 
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OVULATION INDUCTION IN WOMEN WITH PCOS:  AN EVIDENCE BASED 
APPROACH 
 
6.1 INTRODUCTION 
Polycystic ovary syndrome (PCOS) is the most common endocrinopathy in women of reproductive 
age.  In 1935 Steyn and Leventhal1 described the association of amenorrhoea, obesity, infertility, 
hirsutism and bilateral enlarged ovaries.  To date the diagnosis in use remain topical and 
controversial.  There are two definite schools of thought regarding the diagnosis of PCOS.  In the 
UK the classical ultrasound features2 are the cornerstone of the diagnosis, which includes the 
clinical and biochemical presentation.  On the contrary, in the USA, PCOS is diagnosed on the 
clinical and biochemical evidence with the exclusion of CAH, hyperprolactinaemia and 
hypothyroidism3. 
 
In 2003 the Rotterdam consensus statement4 was made to give clinicians guidance in the diagnosis 
of PCOS. This statement concluded that the diagnosis of PCOS can be made if two of the following 
three features are present: chronic anovulation; polycystic ovaries on ultrasound; 
hyperandrogenism/hirsutism with the exclusion of other diseases causing hirsutism.   
 
Familial clustering of cases suggests that genetic factors play an important role in the diagnosis of 
PCOS.  Using a candidate gene approach, Franks et al5 found evidence for the involvement of two 
key genes in the aetiology of PCOS.  They suggest that the steroid synthesis gene CYP 11a and the 
insulin VNTR regulatory polymorphism are important factors in the genetic cause of PCOS.  It is, 
however, unlikely that these two are the only genes involved in the aetiology of this complex 
syndrome. 
 
On the basis of the theory that hyperinsulinaemia negatively effects ovulation and that it is an 
important role-player in the pathophysiology of PCOS, it is postulated and has been proven that 
insulin sensitisers may improve the endocrine imbalances and result in normal menses, ovulation 
and normalisation of hyperandrogenism3.  However, in our own study, Chapter 4, we could not 
confirm the above finding.  It is also known that obesity on its own, and in association with 
hyperinsulinaemia, is associated with relative gonadotrophin resistance6.  By using a simple formula 
we can isolate the hyperinsulinaemia/insulin resistant patient and commence with a combination of 
weight loss and insulin sensitisers.  At this stage the HOMA (homeostasis model assessment) has 
been proven to be of great success in identifying insulin resistance7. 
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HOMA = fasting insulin x fasting glucose.  
22,5  
 
The value of more than 2.5 is generally accepted as insulin resistant, the same is true for a fasting 
insulin level of more than 17 IU/ml. Obesity is defined as a BMI of greater than 30kg/m2 and is 
found in 30 – 50% of women with PCOS8. As mentioned, obesity on its own is associated with 
ovulation resistance.  A minor weight loss of 5% often result in normalisation of cycles and 
ovulation9. 
 
Clomiphene citrate, an anti-estrogen, is the drug most regularly used for ovulation induction.  The 
primary site of action is the hypothalamus where it binds to estrogen receptors and blocks the 
negative feedback effect of circulating estrogens and ultimately results in an increase in 
gonadotrophin releasing hormone secretion10.  
 
The aim of this chapter is to address the approach in managing the patient with PCOS who desires 
to have a baby. This chapter will summarise the findings of the thesis and is presented as a current 
opinion. 
 
6.2 THE IMPACT OF OBESITY ON THE REPRODUCTIVE SYSTEM AND THE 
SUBSEQUENT EFFECT OF WEIGHT LOSS 
In a review by Norman et al11, the association between obesity and women with PCOS was 
highlighted with the emphasis on the effect of obesity on the reproductive system.  Using the 
classification of body mass index (BMI, weight in kg per height in m2), in the United States 60% of 
the adult population are overweight (BMI ≥ 25kgm-2 ) and 22% are obese (BMI ≥ 30 kgm-2 )12. This 
rising prevalence is an important health issue due to the clear association of obesity with an 
increased risk of impaired psychosocial health, type 2 diabetes mellitus, cardiovascular disease 
(CVD), osteoarthritis, sleep apnoea and breast and uterine cancer13. 
 
Reproductive processes are influenced by body weight and reproductive dysfunction will occur in 
both positive and negative extremes of body weight14,15. A direct relationship between menstrual 
irregularity and the degree of obesity in women of reproductive age was reported by Hartz et al16. 
Furthermore, once conception is achieved and increased risk of pregnancy complications and 
miscarriage may result with increased weight17,18.  
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Women with PCOS constitute a significant proportion of the infertile population. Obesity 
prevalence estimates in PCOS range from 35% to 63%19,20. As a primary treatment modality, 
weight loss should be the initial treatment aim in all, obese, infertile women. Resumption of 
ovulation occurred with weight losses of 5,5 - 6,5 kg in anovulatory women21-23.  The NIH 
document ‘Clinical Guidelines on the identification, evaluation, and treatment of overweight and 
obesity in adults’ recommends a multifaceted approach to treating obesity. (Table 1).24 
 
Norman et al11 concluded that weight loss should be the first course of action in obese, infertile 
women. This can be difficult to achieve and maintain. Principles identified, to succeed in weight 
loss, in the general population and in obese infertile women include adoption of healthy eating 
principles and moderate amounts of low-intensity exercise. Modifying additional factors such as 
alcohol consumption, smoking, cognitive behaviour therapy, and use of a group environment can 
increase the long-term success and maintenance of weight loss and reproductive and metabolic 
improvements.  
 
A prospective randomised controlled trial25 was conducted to assess the effectivity when metformin 
is added to C/C, compared to C/C alone in primary ovulation induction protocols(Chapter 4). It was 
observed that all patients ovulated with a BMI<27. With a BMI>27 there was no difference in 
ovulation between C/C alone or the combination of metformin and C/C. In a study by Legro et al26, 
a significant higher rate of live births in women with a BMI less than 30 was noted when compared 
to those with a BMI more than 30. Neveu et al27 observed a better outcome when metformin was 
added in the more obese group(BMI 27-35). The same observation was seen by Nestler et al28. A 
study by Palombo et al29 could not be compared, because they excluded women with a BMI more 
than 30. From these results it is clear that obesity plays a significant role in the fertility prognosis of 
the infertile patient. In this study25 performed at our institution, weight/BMI (P=.009) was the major 
predictive factor in ovulation outcome.  In figure 1 it is clear that all patients ovulated when the 
BMI was less than 27.  This is an important finding and supports current literature to optimize the 
BMI first, loose weight if needed, before commencing with any ovulation induction regimen30. 
 
Other significant factors observed in this study were SHBG (sex hormone binding globulin) P=.036 
and 17hydroxy progesterone (17OH Progesterone) P=.027 (Chapter 4). The variable SHBG was a 
significant factor and positively associated with ovulation. The physiological effect of an increase 
of SHBG is a lowering of the free androgen index and this may lead to an improved ovulation 
outcome. Abdominal fat is related to decreased SHBG and increased androgenicity in infertile 
women.11 Increased androgen production and reduced binding of androgens to SHBG contributes to 
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hyperandrogenism resulting in anovulation through inhibition of follicular maturation. In a study by 
Ghazeeri et al31 rosiglitazone was administered to 25 obese, CC-resistant, PCOS women who 
desired pregnancy. They observed a significant improvement in ovulation rates when rosiglitazone 
was added to C/C in this study. One of the important findings was a significant rise in SHBG in the 
group of women treated with rosiglitazone. Several other investigators have similarly observed an 
increase in SHBG and a decrease in testosterone and androgenicity with improved conception rates 
in patients with weight loss30,32. 
 
6.3 METFORMIN vs CLOMIPHENE: WHICH DRUG TO OFFER WHEN? 
6.3.1 Is there a place for Metformin as a primary (1st line) drug? 
Insulin resistance and concomitant hyperinsulinaemia are frequently found in obese PCOS women 
(65%)33. The incidence of insulin resistance among lean PCOS women is nearly 20%32.  This 
results in hyperinsulinaemia and enhances the LH driven production of androgens from ovarian 
theca cells33.  Hyperinsulinaemia, insulin resistance and an increase in androgen production are all 
linked together in the PCOS patient34,35.  It is also known that patients with PCOS and insulin 
resistance are more resistant to ovulation induction. Is the answer in the management of infertile 
PCOS women then the use of insulin sensitisisers?   
 
Recently four prospective randomised controlled trials were published26,27,29,36.  The primary aim of 
these studies was to compare C/C with metformin alone or in combination when studied as primary 
ovulation induction agents in women with PCOS.(See Chapter 4:  Discussion) In our study25 
(chapter 4), we prospectively randomised 107 patients and 17 (16,3%) patients were lost to follow 
up.  In the study by Moll et al36, they lost 63 (27,6%) patients to follow up.  In their study more 
patients were lost in the metformin group, which might have been due to the side effects. In 
contrast, in our study a similar number of women were lost to follow up in the two groups studied. 
It was observed that the combination of metformin and C/C had a 6% better ovulation rate as C/C 
alone, however this finding was not statistically significant. Similar conclusions were drawn by 
Moll et al36 , Legro et al26 and Neveu et al27 . These authors concluded that metformin should not be 
added to C/C in primary ovulation induction regimens in patients with PCOS.  
 
6.3.2 What is the proposed role of Metformin in ovulation induction protocols? 
As discussed, it was shown that there is currently no benefit for metformin in primary ovulation 
induction protocols in women with PCOS.  Two review articles were published recently37,38.  In the 
one review37 two important articles were not included in their analysis, and in the other38 only two 
articles were mentioned in the C/C-resistant group with the data set very heterogenic. (See Chapter 
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3:  Discussion) Based on the above-mentioned facts and the fact that C/C-resistance is a major 
problem in the handling of the PCOS patient, we performed a meta-analysis with more articles to 
our disposal and according to the selection criteria as outlined39 (See Chapter 3). We obtained data 
from four prospective randomised double blind trials and two prospective randomised (not double 
blind) trials. The data on the first four articles40-43 clearly showed a statistical significant effect in 
favour of ovulation with addition of metformin in the clomiphene resistant patient. When the data of 
the two prospective randomised articles44,45 were pooled with the first mentioned data set it further 
confirmed the positive effect on ovulation with the addition of metformin in the C/C-resistant 
patient(figure 2), (See Chapter 3, figure 3). Based on this review it can be concluded that metformin 
is highly effective in achieving ovulation in the C/C-resistant PCOS patient. We also recommend 
that all obese PCOS patients seeking fertility help should be guided using a lifestyle modification 
program that should include weight-reducing diet and exercises23,30. When this goal is achieved, the 
patient can be started on C/C, and only if C/C-resistance is present, metformin should be added to 
achieve ovulation.  
 
6.4 THE FORGOTTEN MALE FACTOR? 
In general there is quite a poor level of understanding and evidence regarding the profile of the 
semen analysis of the general population. Many male populations have been proposed to be the 
mirror image of the semen analysis of the general population. We believe that possibly the best 
reference group to study the semen profile in a general population is the semen of partners of 
women who have been diagnosed to have chronic anovulation/PCOS. The thresholds used for 
subfertility are those suggested by Van der Merwe et al46 in their recent review:  0-4% normal 
forms;  <30% motility;  <106/ml.  
 
It is important to note that in PCOS patients the clinician needs to take into consideration that not 
only anovulation needs attention, but also that in up to 50% of these patients the male factor also 
needs attention to assist in achieving a successful outcome in these couples.  These lower thresholds 
is first of all not absolute, but a continuum guiding the clinician to respond to a semen analysis.   In 
the case of PCOS, the female factor (anovulation) should obviously be corrected. Although 50% of 
these patients had a male factor according to the definition used, it is also important to note that + 
13-14,5% of these factors were serious (azoospermia, triple parameter defects and double defect)47. 
(See Chapter 5) 
 
In PCO studies it is important to take the male factor into account, especially if two 
groups/treatment modalities are compared prospectively. Even a single sperm defect, e.g. severe 
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sperm morphology (P Pattern) can have an effect in follow up especially if pregnancy is the 
endpoint of the study. We seldom observe that the male factor is outlined in PCO research. 
 
6.5 CONCLUSION 
The diagnostic criteria of women with PCOS remains controversial. It is however extremely 
important to adhere to the current Rotterdam consensus statement for clinical and research 
purposes. 
 
When addressing the issue of women with PCOS who desire to fall pregnant, successful ovulation 
induction is the first hurdle to conquer. In obese PCOS women, the cornerstone of management is 
weight loss and an active exercise programme. As little as 5% weight loss results in spontaneous 
ovulation. 
 
Clomiphene citrate is still the first drug of choice for ovulation induction in women with PCOS. 
Only when C/C-resistance is present, metformin should be added to achieve successful ovulation. 
 
One important factor frequently ignored or neglected in women with PCOS is the semen analysis. 
50% of partners of women with PCOS can have a male factor with 13-14,5% serious defects47. We 
need to address this important factor when managing the women with PCOS, may it be in clinical 
practise or in research projects, especially where the endpoint is pregnancy outcome. 
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Table 1.  National Institute of Health Clinical Guidelines for long-term treatment of 
overweight and obesity 
 
Effective weight loss and long-term results – National Institute of Health Guidelines 
1. Sensible diet and changed eating habits for long-term 
2. Effective physical activity program sustainable long-term 
3. Behaviour modification, reduction of stress, wellbeing 
4. Combination of dietary and behaviour therapy and increased physical activity 
5. Social support by physician, family, spouse, peers 
6. Smoking cessation and reduction in alcohol consumption 
7. Avoidance of “crash diets” and short-term weight loss 
8. Minor roles for drugs involved in weight loss 
9. Avoidance of aggressive surgical approaches for majority 
10. Adaptation of weight loss programmes to meet individual needs 
11. Long-term observation, monitory and encouraging of patients who have successfully 
lost weight 
Adapted from 24 
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FIGURE 1.  Effect of BMI on ovulation success 
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Figure 2. 
Group 1: Four trials where the addition of metformin was randomised in a prospective double-
blind placebo controlled fashion in the CC resistant patient 
Group 2: Two trials where the addition of metformin was prospectively randomised in the CC 
resistant patient 
 
n/N = the number of women where ovulation induction was achieved / the total number of women in the group 
 
Adapted from 39 (See Chapter 3, figure 3) 
 
  
